Acute hepatic decompensation, e287
Acute hydrocephalus, 95, 1646
Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), 1609
electrodiagnostic studies of, 1610–1611
pathology of, 1609–1610
Acute interstitial pancreatitis, e298
Acute kidney injury (AKI), 130, 711, 750
chronic kidney disease and, 135, 1655
in cirrhosis, e288
classification of, 1654–1656
clinical outcomes, 135
clinical presentation of, 1654–1656
coagulopathy management, e286
definition of, 1653
epidemiology, 1654
established management of, 1661–1662
prerenal AKI vs., 1654t
urine outflow, obstruction to, 1655
etiologic diagnosis of, 1662–1663
in HIV-infected patients, 1132
infection management, e286
in intensive care unit, 131t
ischemic, 132
KDIGO, 1653, 1667t
laboratory tests, 1654t
liver transplantation and, 832
major surgery and, 1657
management of, 1659–1662, e285–e286
avoidance of nephrotoxins, 1661
fluid resuscitation, 1660
fluid therapy, 1660–1661
renal protective drugs, 1661
vasoactive drugs to restore MAP, 1659
mechanical ventilation and, 1659
metabolic derangements, management of, e286
nephrotoxins and, 1658
pathogenesis of specific syndromes, 1656–1659
abdominal compartment syndrome, 1659
hepatorenal syndrome, 1657–1658, 1657t
intravascular hypertension, 1659
radiocontrast-induced nephropathy, 1658–1659
rhabdomyolysis, 1658
sepsis, 1656–1657
postoperative, 564
prognosis of, 1663
renal function, assessment of, 1653
renal protective drugs, 1661
in ICU, 1654
in sepsis and septic shock, 428, 1656–1657
staging, 1654t
Acute Kidney Injury Network (AKIN), 130, 564
Acute liver failure (ALF). See also Acute-on-chronic liver failure (ACLF)
cause/prevalence/evaluation, e282t
defined, e281
diagnosis, e282, e283t
epidemiology, e281
hepatic encephalopathy, e281
intracranial hypertension, e281–e282
intracranial pressure monitoring, e286–e287
liver transplantation for, e286
multiorgan system failure, e281
therapeutic hypothermia in, e287
treatment acute kidney injury, e285–e286
cardiopulmonary complications, e285
etiologic-specific management, e282–e283, e283f
HE/cerebral edema/seizures, e283–e285
Acute lung injury (ALI), 134, 697, 1410, e434
comlications of, 1421–1423
outcome of, 1410–1412
pathophysiology of, 1412–1414
in transplanted lung, 1351f
treatment of, 1414–1421
Acute lupus pneumonitis (ALP), e401–402
Acute mesenteric ischemia (AMI), 539, 615.
See also Chronic mesenteric ischemia (CMI); Colon ischemia
aortic dissection, c333
embolus
clinical presentation and diagnosis, e329–e330
outcome, e331
pathophysiology, e329
in situ thrombosis, e331
treatment strategies, e330–e331
mesenteric venous thrombosis
clinical presentation and diagnosis, e332–e333
outcome, e333
pathophysiology, e332
Treatment strategies, e333
nonocclusive mesenteric ischemia
clinical presentation and diagnosis, e332
pathophysiology, e331
treatment strategies, e332
Acute mitral insufficiency, 399–401
free wall rupture and tamponade, 401
left ventricular aneurysm, 401
ventricular septal defect, 400–401
Acute motor axonal neuropathy (AMAN), 1609
and AMSAN, 1610–1611
molecular mimicry and, 1610
pathology of, 1610
Acute motor sensory axonal neuropathy (AMSAN), 1609, 1611
Acute myocardial infarction (AMI), 172, 292, e72. See also Myocardial infarction (MI)
Acute necrotizing fungal rhinosinusitis, 1033
Acute necrotizing ulcerative gingivitis, 1034–1035
Acute normovolemic hemodilution, 1755
Acute-on-chronic liver failure (ACLF)
definitions, e287
Acute pulmonary edema, 112
Acute pulmonary hypertension, 976
Acute renal failure (ARF).
Acute respiratory distress syndrome (ARDS), 1410, e653
Acute retinal necrosis syndrome, e384
Acute salpingitis, 711
Acute respiratory distress syndrome (ARDS)
Acute respiratory distress syndrome (ARDS) score, 268–269
Acute respiratory distress syndrome (ARDS) score (ARDS score)
Acute respiratory distress syndrome (ARDS) score (ARDS score)
Advanced life support (Continued)
circulatory support during CPR, 504
defibrillation for VF and pVT, 503
defibrillator devices, 503–504
drugs during CPR, 507–509
ear-to-tidal carbon monoxide monitoring, 506–507
extracorporeal CPR, 505–506
hemodynamic monitoring, 506
impedance threshold device (ITD), 504–505
magnesium, 511
mechanical CPR devices, 507
physiologic monitoring during, 506
sodium bicarbonate, 510
ultrasound during CPR, 507
Advanced practice registered nurses, 34
Advanced Trauma Life Support (ATLS), 237, 570–571, 693, 729, 1531
Advancement of Medical Instrumentation, 168
Adverse drug events (ADE), e37
Adverse drug reactions (ADRs), e428–e429, e562, e570–571, 693, 729, 1531
Adverse drug events (ADE), e37
American Heart Association, 74
Agnotology, e16
Aggressive fluid loading, 433
Agency for Health Care Research and Quality (AHRQ), 42
Airway occlusion pressure, 1343–1344
Airway pressure, in ventilators, 1343
Airway pressure, during CPR, 507–509
Airway pressure, in mechanical CPR devices, 505
Airway pressure, during CPR, 507–509
Airway pressure, during CPR, 507–509
Airway pressure, in mechanical CPR devices, 505
Anemia, 554, 1745, 1784. See also
Transfusion therapy
after renal transplantation, 871
autoimmune hemolytic, 1786–1787
classification, 1785t
clinical manifestations, 1746
in critical illness, 1785–1786
definition of, 1746
diagnosis of, 1746–1747, 1747t
and transfusions guidelines, 1784–1785
in malaria, 1152
pathophysiology, 1746, 1786
severe, e207
sickle cell, 1788–1789
treatment, 1786
Anergy, 159
Anesthesia
analgesia and sedation in ICU
pain and anxiety, complications from,
e223–224
principles, e223
anesthesiology in critical care medicine,
e216–e217
bedside
ICU procedures and monitoring, e240,
e240t
inhaled anesthetic agents,
e239–e240
principles of, e239
combined, 564
cost savings and patient safety, in ICU,
e222–e223
disease treatment
status asthmaticus, e243
status epilepticus, e242–e243
drug therapy for intubation/MV in status
asthmaticus
anesthetic agents and sedatives,
e243–e244
imaging and interventional radiology,
e244
inhaled anesthetic agents, e244
neuromuscular blocking drugs, e244
umbrella insertion or inferior vena cava
filter, e244
general, 564
global practices, e229, e230t
in hyperbaric treatment, e207
ICU sedation
analgesia and sedation after cardiac
surgery, e237
for neurosurgical patient, e232
sedation in thermally injured patient,
e237
sedative agent, ideal, e232–e233
sedative use, pattern of, e233
short-acting inhalational drugs for
long-term sedation, e237
inhaled anesthetic anesthesia
delivery, 558
distribution of, 558–559
uptake from lungs, 558
inhaled anesthetics
barbiturates, 516
benzodiazepines, 561
ketamine, 561–562
narcotics, 559–560
propofol, 561
malignant hyperthermia
acute therapy for, 567
diagnosis, 566–567
signs of, 566t
treatment, 567
minisurgery
bedside diagnostic mini-laparoscopy and
mini-laparotomy, e240–e241
burns and wound debridement, e242
laparoscopic procedures, e241
percutaneous endoscopic gastrostomy,
e242
tracheostomy, e241–e242, e241t
need, e216
neuromuscular blocking agents,
e228–e229
and organ system function
circulatory effects, 559
hepatic effects, 559
respiratory effects, 559
pain and anxiety assessment
about, e224–e225, e224t, e225t
α1–adrenoceptor agonists, e228
analgesics, e227, e227t
barbiturates, e227
benzodiazepines, e225–e226
butyrophenones and phenothiazines,
e227
clonidine, e227
dexamethasone, e226
ketamine, e226–e227
propofol (2,6-di-isopropylphenol),
e226
sedation scoring systems, e225
sedatives used in, e225, e226t
volatile agents, e227
postoperative care
acute kidney injury, postoperative, 564
critical illness polyneuropathy and
myopathy, 566
delirium, 565
glucose control, 566
hemodynamic management, 564
hypoxemia, 563
pain and perioperative stress, 563–564
postoperative nausea and vomiting,
564–565
residual neuromuscular blockade,
565–566, 566t
regional, 564
relaxants, problems with, e229
risk assessment
APACHE score, e218
ASA classification, e217–e218, e217t
cardiac risk and anesthetic risk in ICU
patients, 222t, e218–e222, e218t,
e219t, e220t–e221t
sedation protocols, e230
daily interruption of, e230–e232,
e231f, e231t
doses of sedation and analgesic drugs,
e232, e234f, e235f
doses of sedation drugs, e232
sedation vs. nonsedation, e232
techniques and clinical states
acute respiratory distress syndrome,
562
patient with head injury, 562
patient with shock, 562–563
topical, e141
Anesthetics, 312
Anthrax, 1146–1149, e560
Anthracyclines, 1812
Anterior superior iliac spine (ASIS), e60
Atrial natriuretic peptide
See ANP.
Anorexia of aging, 758
Annelid worms, e513
Ankylosing spondylitis (AS), e396–e397
Ankle-Brachial Index, 579
Anion gap–associated metabolic acidosis
Anion gap acidosis, 1710–1712
Anion gap, 1705
Anidulafungin, 1873t
Angiotensin receptor blocker (ARB), 404,
481, 553, 687, 761, 914, 921, 1188, 1250, 1712
Angiotensin II, 1192
Angioprotein-2, 134
Angiostrongylus cantonensis, 1011
Angiotensin-converting enzyme (ACE)
hinhibitor, 404, 481, 553, 687, 761, 914, 921, 1188, 1250, 1712
Angiotensin II, 1192
Angiotensinogen, e341t
Angiotensin receptor blocker (ARB), 404,
553
Anidulafungin, 1873t
Anion gap, 1705
calculation of, 1705
increase in, 1705
Anion gap acidosis, 1710–1712
diabetic ketoacidosis and, 1710
etiologies of, 1710
lactic acidosis and, 1711
toxic ingestions and, 1711
treatment of, 1713
Anion gap–associated metabolic acidosis
(AGMA), e352
Ankle-Brachial Index, 579
Ankylosing spondylitis (AS), e396–e397
Annelid worms, e513
Anorexia of aging, 758
ANP. See Atrial natriuretic peptide
Antenatal fetal testing, 949
abnormal, 953–954
biophysical profile, 952–953, 953t
contraction stress test, 951–952
nonstress test, 949–951
Anterior cerebral artery (ACA), 770
Anterior superior iliac spine (ASIS), e60
Anthracelines, 1812
Anthrax, 1146–1149, e60
by Bacillus anthracis, 1146
clinical manifestations, 1147
Bedside diagnostic mini-laparoscopy/mini-laparotomy, e240–e241
Bedside ICU procedures and monitoring, e240, e240t
Bedside index for severity in acute pancreatitis (BISAP) score, e298
Bedside techniques, feeding tube placement gastrointestinal tract, functional status of, e133
hospital resources, e133
motility agents, e133
Bedside ultrasound. See Ultrasound imaging
Beginning and Ending Supportive Therapy
Beer–Lambert law, 204
Bedside techniques, feeding tube placement gastrointestinal tract, functional status
Bedside ICU procedures and monitoring, 1884

Biliary disease, 614
Biliary obstruction for pancreatic inflammation, e303
Biliary pancreatitis, 301
Bladder, 623
Billing, computerized, e39
Binary data, e21
Bioavailability, drug, e242
Biochemical identification, e372
Bioevent triage management, e546–e547
Biofilm formation, 1043
Biomedical cardiology, 172
Biologic agents, e557
category A, e560t–e561t
category B & C, e562t–e563t
high-consequence, e564, e566
Biologic disasters, 1572
Biomarkers, 518
Biophysical profile (BPP), 952–953, 953t
Bioreactance cardiography, 173
Bioreactance devices, 173
Bioterrorism and biologic threats, e551.
See also Biologic agents
care teams, e568, e569
classification and initial treatment, e557
decontamination and first receivers, e554
health care facilities and, e567
assessment hospitals, e567
frontline facilities, e567
treatment centers, e567
historical perspective, e551–e553
hospital perimeters, e554
identification of bioterrorism event, e559t
initiatives in United States, e553–e554
intensivist, role and expectations of,
e556–e557
patient under investigation, e568
personal protective equipment in ICU, e566, e567, e559, e564f
planning and augmenting responses, e557, e558t
PPE recommendations, e567–e568
types of decontamination, e554–e556
ventilator triage, 566t, 567t, 5559, e564
Biotrauma, 1394
Biphasic anaphylaxis, 487
Biphasic defibrillators, 304
Biphasic truncated exponential (BTE) waveform, 504
BIS. See Bistable analysis
Bispectral index (BIS) scale, 319, e217, e225
Bisphosphonates, for hypercalcemia of malignancy, 1698
Bivalirudin, 404, 1186, 1772, 1775
Bladder injuries, 716
Bladder irrigation, 1075
Bladder pressure measurements, e92
Bladder ultrasound units, 709
Blades, e162
curved blade, e162
drothacal tubes (ET), e162–e163, e163t
malleable stylet, e163, e163f
straight blade, e162
use, e162–e163, e163t
Blatchford scoring system, e254
Bleeding
blood volume measurement in, 306
Bleomycin, 1811
Blind nasal intubation, 729
Blood
flow, 126–128 (see also Cardiovascular system)
loss, chronic, e253
and serum markers, 391
viscosity, 314
volume estimation, difficulties in, 304–305
Blood-borne pathogens. See also Emerging pathogens; Respiratory pathogens
hepatitis viruses, 58–60, 60t
human herpes viruses (HHV), 60–61
human immunodeficiency virus (HIV), 57–58
Blood-brain barrier (BBB), e282
Blood cells, collection of, 878
Blood culture, for invasive candidiasis, 1090–1091
Blood flow autoregulation, 1250, 1251f
Blood gas values, e198
Blood glucose control, in CPB surgery patients, 670
Blood pressure (BP), 91, 127–128. See also Cardiovascular system
blood flow and, 126–128
Chronic kidney disease (CKD) on, 137
curve, 127
generation, 126–128
management, 91
treatment of, 95
Bloodstream nosocomial infections
catheters
clinically protective antimicrobial-coated, insertion of, e48
coated with benzalkonium chloride, e44
coated with chlorhexidine and silver sulfadiazine, e45–e46
coated with minocycline and rifampin, e46–e47, e47t
coated with silver–platinum–carbon, e44
silver-coated, e44
CRBSI, reduction in, e45
cutaneous antisepsis with chlorhexidine, e45
diagnosis, e42–e43
dipping catheters in antibiotic solutions, e44
flushing/locking of catheter lumens with antibiotic-anticoagulant solutions, e48
guidewire exchange of vascular catheters, e47
Catheter-associated urinary tract infections (CA-UTI), 958, 961, 1071, 1072t. See also Urinary tract infection (UTI) impact of, 1072–1073 Catheter-related bloodstream infection (CRBSI), 540, 1043–1049. See also Bloodstream nosocomial infections causative organisms, 1043 clinical manifestations, 1044 CVC placement and, 1043 definitions of, 1044 diagnosis, 1044–1046, 1045t, e43 acridine orange cytoplasm leukocyte technique, 1043 differential time to positivity, 1045 fluorescence in situ hybridization on peptide nucleic acid probes, 1045 quantitative catheter cultures, 1046 semi-quantitative roll-plate catheter culture, 1045 simultaneous quantitative blood cultures, 1044–1045 exit-site infection, 1044 management of, 1048–1049 Candida, 1049 coagulase-negative staphylococci, 1048 Enterococcus, 1049 gram-negative bacilli (GNB), 1049 Staphylococcus aureus, 1048–1049 pathogenesis, 1043–1044 port-pocket infection, 1044 preventative strategies, 1046–1048, 1046t antimicrobial catheter-lock solutions, 1046–1047 antimicrobial impregnation of catheters, 1047–1048 CHX-based preparation, 1046 maximal sterile barrier, 1046 silver-impregnated catheters, 1048 significantly reducing, e45 tunnel infection, 1044 Catheter-tunneling-transducer system, 166 Cat-scratch disease, 1039 Caudate lobe, 631 Caustic ingestion, e471–e472 clinical manifestations, e471 management, e472 Caustic injuries, e318 CA-UTI. See Catheter-associated urinary tract infections CAV. See Cardiac allograft vasculopathy Cavitary lesions, 649 CBC. See Complete blood count CBF. See Cerebral blood flow CBN. See Contact transmission necrosis CCB. See Calcium channel blockers CCC. See Cholangiocarcinoma CCM. See Critical care medicine CCO. See Continuous cardiac output C-collar, 728 CD14, 420, 420t CDAD. See C. difficile-associated disease CDI. See Central diabetes insipidus C. difficile-associated disease (CDAD), 991–992 diagnosis of, 991 pathogenesis of, 991 treatment of, 992 CD4+ lymphocytes, 158 CD (cluster of differentiation) numerical designation, 155 CDR. See Clinical decision rules Cemiz, electrolytes in, 1830t Cefazolin, 1839t Cefepime, 1860t and nephrotoxicity, 1655t Cefaroline (Teflaro), 974 Cefazidine, 1860t and nephrotoxicity, 1655t Cefazidime/Avibactam (Avycaz), 975 Cefotaxime, 1859t and nephrotoxicity, 1655t Cefuroxime, 1859t t Cefuroxime/Tazobactam (Zerbaxa), 974 Cefoxione, 1859t and nephrotoxicity, 1655t Celiac artery, e121 Cell salvage, 1755 Cellular and tissue effects, e100–e200 Cellulitis, 999 Cemiz, Fahrenheit to, 1827t Cerebral blood flow (CBF), 310–313, e281, 314–315 imaging of, 184f Intracranial pressure assessment/brain death confirmation, 328–329 cerebral blood flow (CBF) about, 83 measuring, 83–84 regulation of, by carbon dioxide, 85 regulation of, by oxygen, 84–85, 84t CKD on, 137e complications, in CPB surgery patients, 668 dysfunction in septic shock, 427, 427t imaging of, 310 infections of, 1008–1026 (see also Neurologic infections) metabolism, 83 in muscle involvement, e394 treatment options head trauma, 93–94 intracerebral hemorrhage (ICH), 95 ischemic stroke, 96 seizure control and status epilepticus, 94 subarachnoid hemorrhage (SAH), 94–95 Central pontine myelinolysis (CPM), 830, 833 Central venous access catheter and site selection, e111–e113 nontunneled CVC, e110–e111 port catheters, e110 Central venous cannulation, e54 Central venous catheter (CVC), 1043, 1483, 1501, e64–e65, e110. See also Catheter-related bloodstream infection (CRBSI) nontunneled, e110–e111 Central venous pressure (CVP), 126, 165, 172, 173, 181, 234, 381, 426, 633, 658, 1833 reading of, 184f Centrifugal pump, 1428 Centruridales, e509 Cephalosporins, 1859t–1861t for empyema, 1066 Cerebral arterial circulation, 325 Cerebral arteriovenous malformation, 325 Cerebral autoregulation, 85–86, 85f and burn injury, 677 and sepsis, in CPB surgery patients, 670 and uricosuria, 1483 Cerebral blood flow (CBF) and glucose uptake, 72 cerebral blood flow (CBF) about, 83 direct measurement of, 326–327, 327t and oxygen monitoring, 329–330 cerebral microdialysis, 330 cerebral vasospasm detection, 328 intracranial pressure assessment/brain death confirmation, 328–329
Delirium (Continued)

Dermatomyositis, e414
Dermatologic disorders (DD), 1082
Depression, 74–75
Dephlogisticated air, 1401
Deoxygenated blood, 126
Denosumab, for hypercalcemia of bone, 1437
Dengue shock syndrome, 1165
Dengue fever, 1164–1166
Dendritic cells (DCs), 155, 156
Delirium Detection Score (DDS), 1623

Continued...
Index 1897

End-of-life (EOL), 1559

definition of, 1018
diagnosis, 1019–1020
nonviral causes of, 1019
pathophysiology, 1018–1019
postinfectious, 1018
treatment, 1020
viral, 1018, 1019.

Encephalopathy, 635

Endocrinopathy in ICU

Endocrine mediators, GI tract, 142–143

Endobronchial biopsies, e143

End-inspiratory pause, 1343, 1344f, 1348,
End-expiratory pause, 1343, 1344f, 1348,
End-expiratory lung volume (EELV), 1407
End-diastolic volume (EDV), 121

Encephalitis, 1018–1020

definition of, 1018
history of, 12
informed consent and right to refuse
treatment, 21

prolonging life or accelerating death, 22–23
right to die, 23–24
Endogenous vascoconstrictors, 493
Endoscopic drainage, e303
Endoscopic mucosal resection (EMR), e262
Endoscopic retrograde
cholangiopancreatography (ERCP),
e143, 618, 638, 1504, e105, e298, e301
in pregnancy, 937
Endoscopic therapy, e273
Endoscopic ultrasound (EUS), e298
Endoscopy, e136
in caustic ingestion, e472
in esophageal obstruction, e316
for lower GI bleeding (LGB)
colonoscopy for critically ill patients,
e265–e266
preparation before, e265
safety for critically ill patients, e264
toxic megacolon, e31
for upper GI bleeding
about techniques, e255–e256
nonvariceal upper GI bleeding, e256
prophylaxis and SRMD management,
e257, e257t
surgery, e257
variceal bleeding, e256–e257
Endothelial leukocyte adhesion molecule-1
(ELAM-1), 383
Endothelin, 456
Endothelium, 136, 536
Endothelium-derived hyperpolarizing factor
(EDHF), 133
Endotoxia, 637
Endotoxin, 418, 585
Endotracheal aspiration, 1054
Endotracheal tube (ETT), 336–337, 337f,
1406, e162–e163, e163t, e193
airway exchange catheter, 186, 186t
direct laryngoscopy, e185
replacement, e181
fiberoptic bronchoscope-assisted
exchange, e186
follow-up care, e186–e187
insertion, depth of, e174

Endovascular revascularization, e327, e333
Endovascular therapy, 96, e326
End-stage liver disease (ESLD), 818
cirrhotic cardiomyopathy and, 820–821
coronary artery disease and, 820
hemodynamic physiology of, 818–819
End-stage renal disease (ESRD), 133, 552,
861. See also Renal transplantation
End-systolic pressure volume relation
(ESPVR), 121, 121f, 396
End-systolic volume (ESV), 124
End-tidal carbon dioxide, 200, 502
End-tidal carbon monoxide monitoring,
506–507
Energy metabolism, thermogenesis and,
290–291, 290f
Enoxaparin, 1185
Enoximone, 408
Enteral feeding, 441, e141, e446, e447t,
e448–e450
access considerations, e449
complication with, e449–e450
formula, choice of, e449
intermediate duration, e133
long term, e132
short term, e132
volume of feeding, e449
Enteral nutrition (EN), 141, 149–150, e132,
e299, e443
Enterolysis, e270
Enterococci, 63
Enterocutaneous fistula
conservative management of, 616
surgical therapy for, 617
Enteropathy, NSAID-induced, e262
Enteroscopy, e266–e268, e318
Enterotoxigenic E. coli (ETEC), 1084
Enteroviruses, 1010
Envus, after renal transplantation,
866–867
Envenomation, e494–e513
marine animals, e509–e513
snakes
native to the United States, e494–e501
not native to the United States,
e501–e507
spiders and scorpions, e507–e509
Environmental Protection Agency, e555
Environmental sensitivity and feedback, 45
Enzymatic therapy, e317
Enzyme immunoassay (EIA), 58, 1087
Enzyme-linked immunosorbent assay
(ELISA), e368, e409
based IMx assay, e867
EOL. See End-of-life
Eosinophilic granulomatosis with
polyangiitis (EGPA), e404
EP. See Evoked potentials
EPC. See Epilepsia partialis continua
Epicardial coronary spasm, 1178
Epidural abscesses, 1022–1024
Epidural analgesia, 636
Epidural catheters, 649
Epidural hematoxia (EDH), 346,
1528–1529
pathophysiology, 1528–1529
Epiglottitis, 1037–1038, e132
Epilepsia partialis continua (EPC), 1589
focal lesions, 1589
inborn errors, 1589
Rasmussen syndrome, 1589
Epinephrine, 110, 389, 507, 1839, e417
for CPB surgery patient, 665
during CPR, 508
in HF, 1196t
Epistaxis, 731
Epithelial barrier dysfunction, 536–537
Epithelium
type 2, 104
type I, 104
Epiteope, 157
Epinephrine, 404, 1260
Epsilon aminocaproic acid (EACA), 391
Epstein–Barr virus (EBV), 60, 61, 838
Epstein–Barr virus-lymphoproliferative
disease (EBV-LPD), 886
Epitiibataide, 1767
Epworth sleepiness scale, 772
EQA. See External quality assurance
Equal pressure point theory, 108
Esophageal tracheal combitube, e160
Esophageal surgery, 651
Esophageal sclerotherapy and pleural effusion, 1502
Esophageal rupture and pleural effusion, 1502
Esophageal pressure, 1406
Esophageal perforations
Esophageal pain, 1182
Esophageal intubation, e316
Esophageal Doppler, 391–392
Esophageal disorders
corrosive injury
complications, e319
diagnosis, e318–e319
presentation, e318
treatment, e319–e320
esophageal obstruction
diagnosis, e316
presentation, e316
steakhouse syndrome, e317
treatment, e316–e317
esophageal perforations
diagnosis of, e320
presentation, 320
treatment, e320–321
foreign bodies
presentation, e317–e318
treatment, e318
medication injury
diagnosis, e321, e322
presentation, e321
treatment, e322
Esophageal Doppler, 391–392
Esophageal intubation, e177
Esophageal obstruction
diagnosis, e316
presentation, e316
steakhouse syndrome, e317
treatment, e316–e317
Esophageal pain, 1182
Esophageal perforations
diagnosis of, e320
presentation, e320
treatment, e320–321
Esophageal pressure, 1406
measurement of, 1372
Esophageal rupture and pleural effusion, 1502
Esophageal sclerotherapy and pleural effusion, 1502
Esophageal surgery, 651
complication of, 651
Esophageal tracheal combitube, e160
Esophageal variceal bleeding, e256
Esophageal varices, e289
Esophagectomy, 646, 1501
Esophagogastrectomy, 646
Esophagogastroduodenal varices, e251, e253
Esophagoscopy, e316
Esophagus, 141
ESVR. See End-systolic pressure volume relationship
ESRD. See End-stage renal disease
Estimation, e20
Estonogen, 927, e42t
ESV. See End-systolic volume
ESWL. See Extracorporeal shock wave lithotripsy
Esmolol, 1115
Ethanol intoxication, e480–e481
acute toxicity, e480–e481
assessment and treatment, e481
clinical manifestations, e481t
withdrawal syndromes, e481–e483
Ethanol therapy, e466
Ethylene diamine tetraacetic acid (EDTA), 1045
Ethylene glycol
concentration, 1834
metabolism of, e465f
poisoning, e465–e466
ETL. See Endotracheal intubation
Etomidate, 318t, 362, e165, e227, e437
ETT. See Endotracheal tube
European Pulmonary Embolism Trial, 1489
European Respiratory Society, 1446, 1473
European Society of Cardiology (ESC), 1181
European Society of Intensive Care Medicine (ESICM), on GI dysfunction, 149, 149t
EuroSCORE trial, 549
Euthanassa, 17
arguments for and against, 17t
nonvoluntary, 17
Euthyroid sick syndrome, 887
Evaporation, 735
EVD. See Extrahepatic biliary disease
Evelomus, 809, 868
Evidence-based medicine (EBM), 10, e16
Evidence summaries, e11
EVLS. See Extracorporeal shock wave lithotripsy
Evoked potentials (EP), 320–321, 321t
Excessive dynamic airway collapse (EDAC), 1521
Exchange transfusion, 1154
Excitation–contraction coupling, 120
Excitatory postsynaptic potentials, 317t
Excitotoxicity, 330
Excretion, drug, e431
Exhalation, 108
forceful, 106
normal, 106
Expanded criteria donors (ECDs), 862
Experimental (clinical trials) study, e22
Expiratory positive airway pressure (EPAP), 1310
Expiratory reserve volume (ERV), 645, 748, 1834
Expiratory sensitivity, 1347
Exploratory laparotomy, e333
Exposure, e22
Extended spectrum β-lactamase (ESBL), 62, 418
External compliance organizations, 42
External jugular vein (EJV), e67
External noninvasive (transcutaneous) pacing, e80
External performance improvement organizations, 42
External quality assurance (EQA), 365
Extracardiac obstructive shock, 453
Extracellular fluid (ECF), 1680
Extracorporeal albumin dialysis, e293
Extracorporeal CPR, 505–506
Extracorporeal life support (ECLS), 1420, 1427
applications of, 1431
background of, 1427–1428
for cardiopulmonary resuscitation, 1431
clinical results, 1429–1430
adult respiratory failure, 1430
cardiac failure in adults, 1430
cardiac failure in children, 1430
neonatal respiratory failure, 1429
pediatric respiratory failure, 1429–1430
technique and physiology, 1428–1429
Extracorporeal Life Support Organization (ELSO), 1428
Extracorporeal membrane oxygenation (ECMO), 239, 420, 669, 1420, 1427
patients on, 239
Extracorporeal shock wave lithotripsy (ESWL), 713
Extrahepatic biliary disease (EBD), 147
Extra-long tracheostomy (XLT), e196
Extravascular lung water (EVLW), 392t, 1415
Extremity trauma, 579
Exubation, 1377–1378. See also Weaning and airway concerns
complications after, e183
failures, 1378
Eye
involvement, e397
oxygen toxicity on, effect of, e201
F
Fabry disease, e536
Face mask, full, 1309
Face shields, 56
Facial bones, forces to fracture, 728t
Facial trauma, 577
contraindications, 727
epidemiology, 728–730
airway management, 728–729
hemorrhage and bleeding, 729–730
wound management, 730
nasal-orbital-ethmoid fractures, 731–733
pathophysiology, 727
patient examination, 730–731
signs and symptoms of, 731
Factitious thyrotoxicosis, e378
Factor deficiencies, systemic diseases with, 1045
Factor Xa inhibitors, 1776–1777
Factor V Leiden (FVL), 1483
Factitious thyrotoxicosis, e378
Factor VIII deficiency, e228
Factor Xa inhibitors, 1776
Facial trauma, 577
contraindications, 727
epidemiology, 728–730
airway management, 728–729
hemorrhage and bleeding, 729–730
wound management, 730
nasal-orbital-ethmoid fractures, 731–733
pathophysiology, 727
patient examination, 730–731
signs and symptoms of, 731
Factitious thyrotoxicosis, e378
Factor deficiencies, systemic diseases with, 1741–1742
Factor V Leiden (FVL), 1483
Factor Xa inhibitors, 1776
Eye
involvement, e397
oxygen toxicity on, effect of, e201
Facial trauma, 577
contraindications, 727
epidemiology, 728–730
airway management, 728–729
hemorrhage and bleeding, 729–730
wound management, 730
nasal-orbital-ethmoid fractures, 731–733
pathophysiology, 727
patient examination, 730–731
signs and symptoms of, 731
Factitious thyrotoxicosis, e378
Factor deficiencies, systemic diseases with, 1741–1742
Factor V Leiden (FVL), 1483
Factor Xa inhibitors, 1776
direct, 1777
indirect, 1776–1777
Fetal–placental respiration, 948–949
Fever
about, 296, 296f
acalculous cholecystitis and, 959
algorithm for management of, 960f
approach in, 960–961
blood transfusions and, 959
causes of, 957–960, 958t
drug fever, 959
in HIV-infected patients, 1133
in ICU patients, 957–962
in immunocompromised hosts,
1119–1120
infectious causes, 958, 958t
malignant hyperthermia and, 959
neuroleptic malignant syndrome and,
959–960
noninfectious causes, 958–959, 958t,
984t
pathogenesis of, 957
pattern, 958
pharmacologic cooling and physical
cooling, 296–297
postoperative, 959
in sepsis, 430
serotonin syndrome and, 960
thromboembolic disease and, 959
treatment of, 961–962
FBAE. See Free fatty acids
Fibrinogen, 431
Fibrin degradation products (FDPs), 1730,
1730t
Fiberoptic bronchoscope-assisted exchange
for bronchoalveolar lavage, e142–e143
complications, e144, e144t
contraindications, e143–e144
diagnostic and therapeutic
acute upper airway obstruction, e512
airway management, e145–e146, e145t
atelectasis, e146–e147
bronchopleural fistula, e151
central airway obstruction, e152–e153
foreign body removal, e152
hemoptysis, e147–e148, e147t
inhalation injury, e152
noninfectious pulmonary infiltrates,
e150–e151
respiratory infections, e149–e150
status asthmatics, e151
traumatic airway injury, e151
ventilator-associated pneumonia,
diagnosis of, e148–e149
general considerations, e141
mechanical ventilation, e142
protected specimen brush (PSB), e143
quantitative BAL/PBR, e143
sedation and analgesia, e142
topical anesthesia, e141
transbronchial/endobronchial biopsies,
e143
Flexible sigmoidoscopy, 313, e266
FloTrac analyzes, 194, 195, e69
Flow limitation, in lung, 108
Flow–metabolism coupling
anesthetics, 312
arterial carbon dioxide and oxygen,
312–313
cerebral blood flow regulation, 313–314
hypothermia, 311–312
neurogenic regulation, 313
pressure autoregulation, 313, 313f
Flow–volume loop, during mechanical
ventilation, 1345, 1345f, 1354f
FLR. See Future liver remnant
Fluconazole, 722, 1872t
for invasive candidiasis, 1092, 1093t
Fluid and electrolyte disorders, 1680–1700
extracellular fluid, 1680
hypercalcemia, 1697–1698
hyperkalemia, 1692–1693
hypermagnesemia, 1699–1700
hypertension, 1689–1691
hyperphosphatemia, 1695–1696
hypocalcemia, 1696–1697
hypokalemia, 1693–1694
hypomagnesemia, 1698–1699
intracellular fluid, 1680
overview, 1680
phosphate homeostasis, 1694
water metabolism, disorders of, 1681–1682
Fluid attenuation inversion recovery (FLAIR), 310
Fluid balance, in renal system, 133–134
Fluid management in ARDS, 1414–1415
Fluid resuscitation, 432–434. See also Resuscitation
Fluids, intravenous, 1829t
Fluorescence in situ hybridization (FISH) on peptide nucleic acid probes, 1045 Fluorescent antibody test, influenza A, 1162 hybridization (FISH) on
Fluorescence
Fluid resuscitation, 432–434.
Fluid management in ARDS, 1414–1415
Fluid balance, in renal system, 133–134
Fluids, intravenous, 1829t
Fluorescence in situ hybridization (FISH) on peptide nucleic acid probes, 1045 Fluorescent antibody test, influenza A, 1162 hybridization (FISH) on
Fluorescence
Fluid resuscitation, 432–434.
Fluid management in ARDS, 1414–1415
Fluid balance, in renal system, 133–134
Fluids, intravenous, 1829t
Fluorescence in situ hybridization (FISH) on peptide nucleic acid probes, 1045 Fluorescent antibody test, influenza A, 1162 hybridization (FISH) on
Fluorescence
Fluid resuscitation, 432–434.
Fluid management in ARDS, 1414–1415
Fluid balance, in renal system, 133–134
Fluids, intravenous, 1829t
Fluorescence in situ hybridization (FISH) on peptide nucleic acid probes, 1045 Fluorescent antibody test, influenza A, 1162 hybridization (FISH) on
Fluorescence
Heart rate variability (HRV), 208
Heart, structure of. See also Cardiovascular system
action potential, 117–119, 118f
cardiac myocytes, 117, 118f
electrical cycle, 117, 118f
resting membrane potential, 117
Heart transplantation, 801–813
cardiac allograft dysfunction, acute, 803–805
management of, 805
primary, 804, 806t
secondary, 804–805, 804f
cardiac allograft rejection
acute antibody-mediated, 806–807, 807f, 807e
acute cellular, 806, 806f, 806t
hyperacute rejection, 805–806
surveillance of, 807–808
cardiac allograft vasculopathy after, 810–811, 810f
contraindications for, 802t
donor selection, 802
evaluation work-up prior to, 802t
immunosuppressive strategies, 807
antirejection, 809–810
induction, 808
maintenance, 808, 809t
noncardiac complications
chronic renal failure, 812
infections, 811, 811f
malignancies, 811–812
other, 812
outcomes and survival, 812–813
organ allocation, 801–802
overview, 801
and pregnancy, 923
recipient selection, 802–803
retransplantation, 813
surgical technique, 803
Heart and moisture exchanger (HME), 1313, e237
Heat cramp, 739
Heated humidifiers (HHs), 1313
Heat exhaustion, 739
Heat stroke, 738–739
defined, 739
exertional and nonexertional, 739t
Heat syncope, 739
Heat syndromes, 739t
Heinz bodies, 1787
Helical CT angiogram, e270
Helicopters for interhospital transfers, 69
Heliox, 653, 1401
Helium-oxygen mixture, 1383
therapy, in asthma management, 1462
Heller myotomy, 646
HELLP syndrome, 910, 929, 1585
Helmet, noninvasive ventilation by, 1309, 1309f
HELP. See Hospital Elder Life Program
Helper T cells, 115
Hemagglutinin, 1160
Hematemesis, e321
Hematocrit, 302, 303, 305, e253
measurements, 459
Hematologic manifestations in RA, e394
Hematomata, e111
Hematopoiesis, 1784
Hematopoietic stem cells (HSCs), 1784
Hematopoietic system and burn injury, 677
Heme-porphyrin test, e264
Hemicircumference, 94, 96
Hemobilia, 638
Hemodialysis in acidosis, 1713
in alcohol poisoning, e466
in lithium poisoning, e461
in salicylate poisoning, e459
and vascular surgery, 694
Hemodialysis, e302
Hemodynamic, e198, e199t
instability, e266, e270f
measurements, 172
models, 124, 124f, 124t
monitoring, 172
basic, 391, 392t
invasive, 391
methods of, 172
values, normal, 181t
variables, 124t
Hemodynamically unstable patients, transfer of, 68
Hemoglobin, 84, 302, 305, 431
measurements, 459
Hemoglobin-based oxygen carriers (HBOCs), 466, 1736
Hemoglobinuria, 1443
Hemolysis, 1744
in G6PD-deficient patient, 1787
Hemolytic anemia
 aplastic crisis in, 1789
from G6PD deficiency, 1787
from red cell injury in circulation, 1787–1788
Hemolytic disease of fetus/newborn (HDFN), 1754
Hemolytic uremic syndrome (HUS), 583, 832, 910, 930, 1253, 1732–1733, 1787
Hemoperfusion (HP), 1674t
Hemoptysis, e147–e148
Hemoperfusion (HP), 1674t
Hemorrhage, 460
massive transfusion protocols, 464–465, 464t, 465t
pathophysiology
 cellular response, 455
circulatory changes, 453
coagulopathy, trauma-induced, 457
inflammatory and immune response, 457
maccirculation, 455–456
metabolic and hormonal response, 453
microcirculation, 456–457
neurohumoral response, 455
oxygen balance, 453–455
red cell substitutes
freeze-dried or lyophilized plasma, 466
hypertonc saline, 466
resuscitative endovascular balloon occlusion of aorta (REBOA), 467
and reduced pulmonary blood flow, 220t
resuscitation, 388
Hemorrhagic stroke, 770
Hemorrhoids, e263
Hemostasis, 423–424
Hemostatic disorders, 583
Hemostatic resuscitation, 464
Hemothorax, 650
and pleural effusion, 1502
Henderson–Hasselbalch equation, 200, 1704
Heparin, 1047, 1839, e286, e333
overdose, 1737
Heparin-induced thrombocytopenia (HIT), 584, 1186, 1483, 1739–1740, 1770–1772, 1771t, 1792–1793, e429
4Ts scoring system for, 1791t
Hepatic artery thrombosis (HAT), after liver transplantation, 834
Hepatic encephalopathy (HE), e281, e283–e285
Hepatic failure, 1585
Hepatic hydrothorax (HH), e289
and pleural effusion, 1502–1503
Hepatic ischemia reperfusion injury, 635
Hyperthermia, 91, 288, 738–744, 1532.
Hypertensive urgency, 1250
Hypertensive encephalopathy syndrome
Hypertensive emergencies, 1250
Hyperresponsive, e391–e392
Hyperphosphatemia, 1695–1696
Hyperperfusion, 1405
Hyperoxia, 113
temperature regulation, 739
and fever, 738t
environmental, 738–739
clinical syndrome, 739–741
and AKI, 1250–1251
myocardial infarction, 1512–1513
hypertrophic cardiomyopathy, 1533
Hyperthyroidism. See also Thyroid disorders
preoperative management of, e381
Hypertonic contrast agents, e316
Hypertonic crystalloid, 387
Hypertonic fluids, 110
Hypertonic saline (HTS), 94, 466, e284
in ICP management, 1533
Hypertiglyceridemia, 429
Hypertrophic cardiomyopathy (HCM), e536, e537
in pregnancy, 921
Hypertrophic obstructive cardiomyopathy (HOCM), 268
Hyperuricemia, management of, 1803
Hyperventilation, 93, 111, 115, 329, 1531,
e284
and ICP, 1534
mechanical, 311
Hypovolemia, 172, 307, 433, e255, e285,
e286
Hypoventilation, 111, 563
Hypothyroidism
See also Neurologic injury
Hypoparathyroidism, e385, e385t
Hypoperoxidase, 133
Hypopituitarism, 474
Hypoxia, 74, 115, 333, 313, 494, 664
and AKI, 133
alveolar, 110
Hypoxic–ischemic encephalopathy, 1441
Hypoxic ischemic injury, 90
Hypoparathyroidism, e385, e385t
Hypoperoxidase, 133
Hypopituitarism, 474
Hypoxia, 74, 115, 333, 313, 494, 664
and AKI, 133
alveolar, 110
Hypoxic–ischemic encephalopathy, 1441
Hypoxic ischemic injury, 90
Inflammation, 157
clinical signs of, 157
Inflammatory bowel disease (IBD), e262
diagnosis
clinical presentation, e310
diagnostic workup, e310–e311
etiopathology, e309, e310t
incidence, e309
mortality, e309
overview, e309, e309t
pathophysiology, e309
toxic megacolon, e309
treatment
medical treatment, e311–e312, e311t
pregnant women with IBD, e313
surgical management, e312
Inflammatory cytokines, 1727
Inflammatory mediators, in MODS
cogulation system, 532–533
complement cascade, 531
neutrophils, 531–532
reactive oxygen metabolites, 531–532
Inflammatory response, 153
Influenza A, 1115, e272f, e312
Influenza, 1100, 1103, 1160–1164
diagnosis, 1100
Influenza virus
Bordetella pertussis, 64
Neisseria meningitidis, 64
Informed consent, 21, 24, e53
Informed consent model, 24
Injury Severity Score (ISS), 701, 762, 1535
Inhibitory postsynaptic potentials (IPSP), 317
Insulin, 91, e341t, e346, e347t, e351
Insulin-like growth factor, e341t
Insulin-like growth factor-binding protein 7 (IGFBP7), 1653
Insulin receptor–related receptor (IRR), e346
Insulin tolerance test (ITT), e366
Insurance-related inequalities, in critical care, 2–3
Integrase strand transfer inhibitors (INSTIs), 1135
Intensive Care Delirium Screening Checklist (ICDSC), 1623–1624, 1624t, e435
Intensive care procedures
abdominal pressure monitoring indications, e90
pitfalls and complications, e92
technique, e92
cricothyroidotomy indications, e91
open cricothyroidotomy, e87
percutaneous cricothyroidotomy, e88
pitfalls and complications, e88
DPA/DPL indications, e85
peritonneal catheter insertion, open technique for, e86–e87
peritonneal catheter, percutaneous insertion of, e85
percutaneous gastrostomy indications, e91
pitfalls and complications, e92
technique, e91–e92
percutaneous inferior vena cava filter placement
fluoroscopy guided, e93–e94
indications, e93
intravascular ultrasonographic–guided, e94
pitfalls and complications, e94
percutaneous tracheostomy indications, e88–e89
pitfalls and complications, e91
technique, e89–e90
Intraoperative endoscopy, e267
Intraoperative blood recovery, 1755
Intramural hematoma (IMH), 273
Intraoperative mechanical ventilation, 551–552
Intraparenchymal hemorrhage (IPH), 347–348, 1528, 1529
Intrapartum fetal surveillance, 953 normal, 954
Intrapericardial pressure, 1329
and pleural pressures, 1239
Intrapleural fibrinolytic therapy, 650, 1502
Intraprocedural airway complications, e196
Intraperitoneal shunt, 190–191
Intrarater reliability, e29
Intrathoracic pressure (ITP), 1265
Intravascular ultrasonographic-guided percutaneous inferior vena cava filter placement, e94
Intravenous acid suppression therapy, e319
Intravenous agents barbiturates, 560
benzodiazepines, 561
ketamine, 561–562
narcotics, 559–560
propofol, 561
Intravenous bolus sedation technique, e235t
Intravenous infusion devices, e209
Intravenous immunoglobulin (IVIG), 440
for necrotizing fasciitis, 1004
in transplantation, 848
Intravenous infusion devices, e209
Intravenous lipid emulsion (ILE) therapy, e465
Intravenous pyelogram (IVP), 716
Intravenous valproic acid, in status epilepticus treatment, 1598
Intraventricular hemorrhage (IVH), 348–349, 1528, 1529
Intubation, 92–93
in asthma patient, 1463
Intubation adjuncts indirect visualization of airway, e171, e172t
tracheal tube introducer or Bougie, e170–e171
video laryngoscopy and rigid fiberscopes, e171–e172
Invasive hemodynamic monitoring, 391
Invasive mechanical ventilation and COPD, 1476–1479
Invasive pressure monitoring, e209
future directions, 170–171
signal processing
electronic filtration and analog-to-digital conversion, 168–169
transduction
transducer design, 168
transducer properties, 167–168
troubleshooting
calibration, 169
frequency response, 169–170
overdamping errors, 170
underdamping errors, 170
zeroing, 169
tubing system
flush systems, 168
tubing, 168
wave transmission
damping, 165–167
natural frequency, 165
Invasive pulmonary aspergillosis (IPA), 1095t, 1096. See also Aspergillosis
Invasive ventilatory support, 1327–1340
Invertase ratio ventilation (IRV), 647, 1419
Invertebrates, venomous, e510–e512
clinical effects, e511
treatment, e511
lodined contrast media, e378
lodixano, and nephrotoxicity, 165t
lohexo, and nephrotoxicity, 165t
IOM. See Institute of Medicine
Iodinated contrast media, e378
Iodinated contrast media (ICM), 1655t
Ioversol, and nephrotoxicity, 1655t
Iopamido, and nephrotoxicity, 1655t
Ipratropium bromide
in asthma management, 1461
in COPD treatment, 1473
IPFP. See Inhibitory postsynaptic potentials
IRDS. See Infant respiratory distress syndrome
Irinotecan toxicity, e523
Iron deficiency, 1746
Irradiation, 1750
Irritable contact dermatitis, e417
IRV. See Inverse ratio ventilation
Isvaconazole
for invasive aspergillosis, 1098t
for invasive candidiasis, 1093t
Ischemia-related edema, 1642
Ischemic bowel, e263
Ischemic cell necrosis, heart transplantation
and, 805, 805f
Ischemic colitis, e262
Ischemic heart disease, in pregnancy, 921–922
Ischemic states, 710. See also Urologic surgery and trauma
Ischemic stroke, 96, 770, 1634–1639
arterial dissections, e1746
cardiogenic embolism, 1635–1636
clinical evaluation, 1636–1637
clinical history, 1636–1637
imaging, 1638–1639
carotid ultrasound, 1639
CT scan, 1638, 1638f
DSA, 1639
MRL, 1638–1639, 1639f
transcranial Doppler, 1639, 1640f
transhrocortic echocardiography, 1639
laboratory studies, 1638
lacunar strokes, 1635
large vessel atherothrombosis, 1635
neurologic examination, 1637
pathogenesis of, 1634–1635
tissue plasminogen activator use, contraindications to absolute, 1636t
relative, 1636t
vascular system examination, 1637–1638
Liver
dysfunction, 340
in septic shock, 428–429
enzymes, 612
failure, 638–639
and spleen injuries, 603
transplantation for ALF, e286
Liver disease, abnormal hemostasis in,
1733–1735
fibrinolysis and, 1734
management of, 1734–1735
presentation, 1734
Liver failure. See Acute liver failure (ALF)
Liver function, assessment and support of,
635–636
Liver resection, 633. See also Hepatopancreatico-biliary surgery patients
hemodynamic monitoring, 633
Liver-small bowel transplant (LSBTx), 855
Liver transplantation, 818–835
in acute liver failure, Kings College criteria for, 827
anesthetic management, 827–829
cogulopathy of liver failure and transfusion, 824, 825f
complications
acute kidney injury, 832
infection, 832–833
neurologic complications, 833
fulminant liver failure and, 824–827
graft-related complications
biliary complications, 835
primary nonfunction and delayed function, 833–834
rejection, 834–835
small-for-size syndrome, 835
LMWH. See Low–molecular-weight heparin
L.N. See Lupus nephritis
Lobar collapse and torsion, 634
Locked-in syndrome, 316
Long QT syndrome (LQTS), e536, e537
Long-term acute care hospitals (LTACHs), 1385
Long-term care, 4–5
Long-term enteral access, defined, e132
Loop diuretics, 1534
for AKI, 1661
Loop of Henle, 132
Lorazepam, 561, 1840, e231, e231t
Loratadine, 1364
Lorazepam, 1264
Lori, 1364
Losartan, e543
Low-density lipoprotein (LDL), 687
Low-dose unfractionated heparin (LDFUH), 1535
Low-efficiency daily dialysis (SEED), 1669, 1670
Lower airway disease bronchiectasis, e391
broncholithiasis, e391
rheumatoid lung nodules, e391–e392
Lower gastrointestinal bleeding (LGB) and acute myocardial infarction, e275
treatments, e273, e274t
defined, e260
diagnosis of
angio-gram, e269–e270
colonoscopy, timing of, e266
computed tomography (CT) scan/magnetic resonance imaging (MRI), e270
endoscopic approach, e264–e266
enterotomy, e270
enteroscopy/capsule endoscopy for critically ill patients, e266–e268
gastric-based tests, e264
heme-porphyrin test, e264
history, e263
immunochemical fecal occult blood tests, e264
laboratory examination, e264
nuclear medicine, e268
physical examination, 263–264
radionuclide scanning, use of, e268–e269
sigmoidoscopy or colonoscopy, e266
small bowel follow-through (SBFT), e270
ultrasound, e270
overview, e260, e261t
pathophysiology
AHRU/AHRUS, e262–e263
angio-lymphatic, e260
bleeding caused by endoscopic treatments, e262
causes of LGB, e263
colic diverticular bleeding, e261–e262
dieulafoy lesions, e262
ischemic colitis, e262
NSAID-induced enteropathy and colonopathy, e262
radiation colitis, e262
ulcerative colitis and Crohn disease, e262
treatment of endoscopic therapy, e273
pharmacologic therapy, e272, e273t
radiologic interventions, e273
resuscitation, e270, e271f, e272f
surgery, e273
Lower inflection point, 1277
Low-extraction drugs, e426
Low-frequency component (LFC), 207, 207f
Low-frequency positive pressure ventilation with extracorporeal CO₂ removal (LPPV-ECCO₂R), 1420
Low–molecular-weight heparin (LMWH), treatment of
Lung
Lung Injury Score (LIS), 1410, 1411t
Lung allocative system (LAS) score, 787, 788f
Lung allocation system (LAS) score, 787, 788f
Lung diffusing capacity, 550
Lung mechanics
airway resistance, 107
death space, 108
flow limitation, 108
muscular force, 107–108
normal pattern of breathing, 108
pleural pressure, 107
position and lung volume, 108
pressure–volume relationships, 106–107
respiratory muscles, 106
work of breathing, 108–109
Lung volumes
candidates for, selection criteria for, 788, 789f
complications after
acute rejection, 799–800, 799f
airway complications, 797–798, 798f
cancers, 800–801
chronic lung allograft dysfunction, 799–800, 800f
infection, 798–799, 799f
primary graft dysfunction, 797–798
recurrence of native lung diseases, 801
donor availability and suitability, 787
ideal donors, criteria for, 787, 788t
end-stage lung diseases and, 787
immunosuppression with, 790–791, 791f, 792f
lung allocation system (LAS) score, 787, 788f
outcomes following
exercise capacity, 796–797
hemodynamics, 795–796
pulmonary function and gas exchange, 793–795, 795f, 796f
quality of life, 796, 797f
survival, 793, 794f
Lymphatic constriction band (LCB), e498, e509
Lymphangiography, 654
Lymphadenitis, 1039
Lymphedema, 654
LVAD. See Left ventricular assist device
LVEDP. See Left ventricular end-diastolic pressure
LVEDV. See Left ventricular end-diastolic volume
LVEF. See Left ventricular ejection fraction
LV end-diastolic volume (LVEDV), 1213
LVESV. See Left ventricular end-systolic volume
LVICF. See Large-volume ice-cold intravascular fluid
LVOT. See Left ventricular outflow tract
LVRS. See Lung volume reduction surgery
LUS. See Lung ultrasound
Lupus anticoagulants, 1742
Lupus nephritis (LN), e398
LUS. See Lung ultrasound
Luteinizing hormone (LH), 366, e341t
Luteinizing hormone–releasing hormone (LH-RH), 710
LVOT. See Left ventricular outflow tract
LVFSWI. See Left ventricular stroke work index
Lymphectasia, 153
Lymphangiography, 654
Lymphatic constriction band (LCB), e498, e504
Lymph nodes, 155
Lymphocytes, 155, 375
Lymphocytic choriomeningitis (LCM) virus, 1010
Lymphokine-activated killer (LAK), 159
Lympholyzed plasma, 466

M
MAAS. See Motor activity assessment scale
Macintosh (curved) video laryngoscope, e172
Macrocirculation, 455–456
Macroolides, 1055
Mechanical ventilation (MV), and AKI, 1659
Meckel diverticulum, e260, e269, e270
Mediastinoscopy, 653
Medicaid, 2, 4–5
Medical advice, signing out against, 28–29, 29t
Medical decision analysis, 1367–1368
Medical early warning score (MEWS), 1405
Medical embolectomy, 1494
Medical emergency teams (MET), 501
Medical infections, 983
Medical intensive care unit (MICU), 1585
Medical journal
Bayesian–Frequentist dialectic, e17
components of article in abstract, e26
background, e27
data analysis, e29
description of sample, e29
discussion and conclusions, e31
measures, e28–e29
objective and hypothesis, e26–e27
presentation of findings, e29–e31
study design, e27–e28
from information to knowledge, e15–e16
motivations for reading
case control study, 23–24
cohort study, 24–25
cross-sectional study, e23
experimental (clinical trial) study, e25–e26
research studies, types of, e22–e23, e23t
statistical concepts, e18, e18t, e19t, e21t, e22t
review and research synthesis, e31
Medicare, 2
Medication injury diagnosis, e321, e322t
presentation, e321
treatment, e322
Medium-chain acyl-CoA dehydrogenase (MCAD), e527
deficiency, e528
Medium-sized vessel vasculitis, e405t
Methylxanthines, in asthma management,
-Methanol
-Methamphetamine, e489
-Metformin-associated lactic acidosis, e473
-Meperidine, 668, e142, e227
-Meropenem, 1857t
-MERRF. See Myoclonic epilepsy with ragged red fibers
-MERS. See Middle East respiratory syndrome
-Mesalamine, and nephrotoxicity, 165t5
-Mesangial proliferative lupus nephritis, e403t
-Mesenteric angiology, e269
-Mesenteric ischemia, 145–146, 146f, 493–494, e123. See Acute mesenteric ischemia (AMI); Chronic mesenteric ischemia (CMI); Colon ischemia
-Mesenteric lymph nodes (MLNs), 146
-Mesenteric venous thrombosis
clinical presentation and diagnosis, e332–e333
outcome, e333
pathophysiology, e332
treatment strategies, e333
-Metabolic abnormalities, in HIV-infected patients, 1132–1133
-Metabolic acidosis, 1662, 1692, 1705, 1710–1713
after liver transplantation, 830
anion gap acidosis, 1710–1712
anticipated changes in, 1831t
causes of, 1831
and COPD, 1476
medications and, 1713–1714
nonanion gap acidosis, 1710–1712
and respiratory acidosis, 1718
treatment of, 1713
-Metabolic alkalosis, 1714–1716
anticipated changes in, 1831t
causes of, 1831–1832
and nephrotoxicity, 165t5
-Methemoglobinemia, 1421, e469–e470
-Methylcobalamin, 1462
-Metabolism, e526
-Metabolic stroke, e535
-Methionine, e526
-CNS physiology in critical illness, 83
drug, e430, e430t
inherited disorders of, e526–e527, e527f
-Methylmalonyl-CoA mutase deficiencies (MTHFR), e536
-Methylene chloride, e470
-Methotrexate (MTX), 1586, e390
-and nephrotoxicity, 165t5
-Meropenem, 1857t
-3,4-methylenedioxymethamphetamine, e489
5,10-methyleneditetrahydrofolate reductase (MTHFR), e336
-Methylmercury, e489
-Methylprednisolone sodium succinate (Solu-Medrol), 878
-Methyl-tert-butyl ether (MTBE), e103
-Methylxanthines, in asthma management, 1461–1462
-Metoclopromide, e133, e135
-Metoprolol, 403
-Metformin, e473
-Metoclopramide, e133, e135
-Methoxamine, 3,4-methylenedioxymethamphetamine, e489
-Methylmalonic aciduria (MMA), e528, e536
-Methanol
-oxidation of, e465–e466
metabolism of, e465f
-Methotrexate, e373
-Metronidazole, 1870t
-Metric prefixes, 1827t
-Metformin, e473
-Micromethods, e526
-Microsphere-based array, e526, 967
-Microalbuminuria, 1461–1462
-Microcirculation, intestinal, 493
-Microarray technologies, e526, 967
-Microbiome, 384
-Microbicidal activity, 418–421, 421t
-cardiac and vascular responses, 426
cytokines, 421–422
hemostasis, 423–424
host genetic factors, 424, 424t
-nitric oxide, 422–423
-Microcirculation, intestinal, 493
-Microdialysis, 330
-Microglia, e339
-Microsphere-based array, e526
-Microvascular circulation, intestinal, 493
-Microbial antigen signaling, 418–421, 421t
-Microvascular perfusion models, e374
-Microvascular perfusion, e374
-Microvascular unit, 137
-Microvesicles, e104
-MIDAS.
-MIM.
-MIDAS.
-MICU.
-MIDAS.
-MIM.
-MICU. See Medical intensive care unit
-MIDAS.
-MIM.
-MICU. See Medical intensive care unit
-MIDAS.
-MIM.
Multiple epidural metastases (MEMs), 1807
Multiple Organ Dysfunction Score, 1848t
Multiple organ dysfunction syndrome (MODS), 416, 700, 1410, e217, e434
Multiple organ failure (MOF), 302 defined, 494 splanchic model of, 494–495
Multiple Sleep Latency Test, 772
Multiple system organ failure (MSOF), 228, 505
Multiplex PCR respiratory virus panel (RVP), 1100
Multisociety Strategic Planning Task Force, 74
Multivariate analysis, e21n
Multivisceral transplant (MVTx) of small bowel, 1652, 827, e282, e457
Nadir pressure, 187
Nafion tubing, 212
NAFLD.
Naloxone, e488
Narcotic, e164
Narcissism, e5–e6
Nasal decongestant agents (NDCA), 990
Narrow QRS tachycardia, 1228–1233
differential diagnosis for, 1228 treatment of, 1233
Narcoxac, e164
gastrointestinal effects, 560
general properties, 559–60
hemodynamic effects, 560
immune function, 560
neurologic effects, 560
pharmacokinetics/pharmacodynamics, 560
respiratory effects, 560
use of, e229
Narrow QRS tachycardia, 1228–1233
definition, 1228
differential diagnosis for, 1228
treatment of, 1233
Narrow-spectrum antibiotics, use of, 975
Nasal decongestant agents (NDCA), 990
Nasal fracture, clinical features of, 731t
Nasal intubation, complications of, 1186
Nasal packing, 729
beta-blockers, 1184
calcium channel antagonists, 1184
clopidogrel, 1184
direct thrombin inhibitors, 1186
fondaparinux, 1186
glycoprotein IIb/IIIa inhibitors, 1185
heparins, 1185–1186
nitroglycerin, 1183–1184
prasugrel, 1184
statins, 1186
supplemental oxygen, 1183
ticagrelor, 1185
Myocardial infarction or cardiac arrest (MICA), 547
Myocardial injury biomarkers of, 1180–1181, 1181f
ecocardiography in, 274–276
Myocardial ischemia, 662
Myocardial oxygen consumption (MVO2), 180
Myocardial remodeling, 1192
Myocarditis, 1182, e403
Myoclonic epilepsy with ragged red fibers (MERRF), 1589
Myoclonus, 514
Myogenic reflex, 130
Myogenic theory, 85
Myoglobulin, 704
Myonecrosis, 704
Myoglobin, 704
Myogenic theory, 85
Myogenic theory, 85
Myoclonus, 514
Myopathy, e244
in asthmatic patient, 1468
Myxedema coma, e382
N
NAAT. See Nucleic acid amplification testing; Nucleic acid amplification tests
N-acetylcysteine (NAC), 539, 635, 636, 809, 827, e48, e282, e457
Nadir pressure, 187
Nafcinil, 1066
and nephrotoxicity, 1655t
Nafion tubing, 212
NAFLD. See Nongenetic fatty liver disease
Naloxone, e488
Narcissism, e5–e6
Narexcor, e164
Nasal decongestant agents (NDCA), 990
gastrointestinal effects, 560
general properties, 559–60
hemodynamic effects, 560
immune function, 560
neurologic effects, 560
pharmacokinetics/pharmacodynamics, 560
respiratory effects, 560
use of, e229
Narrow QRS tachycardia, 1228–1233
definition, 1228
differential diagnosis for, 1228
treatment of, 1233
Narrow-spectrum antibiotics, use of, 975
Nasal decongestant agents (NDCA), 990
Nasal fracture, clinical features of, 731t
Nasal intubation, complications of, 1186
Nasal masks, noninvasive ventilation by, 1307–1308, 1308f
Nasal packing, 729
Nasal pillows, noninvasive ventilation by, 1308, 1308f
NASH. See Nonalcoholic steatohepatitis
Nasoduodenal feeding tube, placement of, e135–e136
Nasoenteric feeding tube, placement of, e135f, e136
Nasoethmoidal fracture, clinical features of, 731t
Nasogastric feeding tube, placement of, e135
Nasogastric lavage, e253–e254
Nasogastric tubes, e319
Nasogastric lavage, e253–e254
Nasogastric feeding tube, placement of, e135
Nasotracheal suctioning, 652
Nasotracheal intubation, 729, e168–e169
Nasopharyngeal mucosa perforation, e176
Nasopancreatic catheters, e306
Naso-orbito-ethmoid (NOE), 729
Nasojejunal feeding tube, placement of,
Nasogastric lavage, e253–e254
Nasogastric tubes, e319
Nasal pillows, noninvasive ventilation by, 1308, 1308f

Natural frequency ($f$)
Natural disasters, e572
Innate immunity
Native immunity. See
National Trauma Data Bank, 702
Native immunity. See Innate immunity
Natural disasters, e572
Natural frequency ($f$), 165
Natural immunity. See Innate immunity
Natural killer (NK) cells, 155
NAPA. See Neurally adjusted ventilatory assist
NCS. See Nonconvulsive seizure
NCSE. See Nonconvulsive status epilepticus
NDMS. See National Disaster Medical System
Nd:YAG. See Neodymium:yttrium aluminum garnet
Near-drowning, 1435t
Near-fatal asthma (NFA), 1453
Near-infrared spectroscopy (NIRS), 199–200, 203, 329, 392, 426 measures, 199
Neck flexion, e158
Neck injuries, 577–578
Neck space infections, deep, 1039–1040
Necrosis, 90
Necrotizing fasciitis (NF), 1000–1006
Fournier gangrene, 1002, 1005f, 1006
Gas gangrene, 1002
Imaging studies for, 1003, 1003t, 1004f, 1004f
Meleney synergistic gangrene, 1001f, 1002f
Pathophysiology of, 1001f
Therapy for, 1003–1006, 1004t
Types I, 1000
Types II, 1000, 1002
Necrotizing infections
anemia, severe, e207
Arterial oxygenation, support of, e207
Closural infections, e206
Head injury, e207
Mucormycosis, e206–e207
Myocardial infarction, e207
Nonclosural bacterial infections, e206
Sedation and anesthesia in hyperbaric treatment, e207
Stroke, e207
Thermal injury, e207
Necrotizing otitis externa, 1030
Necrotizing pancreatitis, e298, e300
Necrotizing soft tissue infections (NSTIs), 989
Needle catheter jejunostomy technique, e137
Needle cricothyroidotomy, 729
Needlestick Safety and Prevention Act of 2000, 57
Neelson and Champagne Confusion Scale (NEECHAM), 1623
Negative inspiratory force (NIF), 647
Negative pressure therapy, 998
Negative-pressure ventilation, 1307
Negative-pressure wound therapy (NPWT), 989
Neisseria meningitidis, 64, 161
Bacterial meningitis by, 1008, 1010, 1015
Nellcor finger, 207
Neocortical dyscognitive focal status epilepticus, 1589
Neodinium:yttrium aluminum garnet (Nd:YAG), 1519
Neomycin-containing topical preparations, 623–624
Neurocrine messengers, GI tract, 141
Neurocrine messengers, GI tract, 143
Neuroendocrine cells, 1413
Neuroendocrine activation in acute injury, 1413
Neuroendocrine neurogenic shock, 478, 480
Neurogenic pulmonary edema (NPE), 92, 476, 1531, 1685
Clinical signs of, 1531
Neurogenic regulation, 313
Neurogenic shock, 385
Cardiogenic shock, 1413
Diagnosis of, 478–480
Hypotension
Adrenal insufficiency (AI), 474
Incidence of, 474
Pathologies of
Cardiogenic neurogenic shock, 475–478
Neuroendocrine neurogenic shock, 478–479
Vasodilatory neurogenic shock, 474–478
Treatment of, 480–481
Neuroimaging
Brain edema
diagnosis, 344–345
Pathophysiology, 344
Herniation syndromes
diagnosis, 342–345
Neuroendocrine shock, 478–480
Subfalcine herniation, 344
Neural trauma, 345–346
Subarachnoid hemorrhage (SAH), 347–348
Neuroendocrine shock, 347–348
Subdural hematoma, 346–347
Spine
Diagnosis, 356–359, 357f, 358f
Pathophysiology, 354
Stroke
diagnosis, 350–352
Pathophysiology, 349–350
Neuroimaging, of status epilepticus, 1593
Neurologic monitoring

Neurologic manifestations, e289–e290, neurologic injury, neurologic disorders, in geriatric patient, neuroleptic malignant syndrome (NMS), neuroleptic malignant hyperthermia, neuroinvasive disease, cerebral function, brainstem auditory-evoked potentials, treatment, physiologic principles, controversies, suppurative intracranial, thrombophlebitis, neurologic infections, 1008–1026, brain abscess, encephalitis, meningitis, subdural and epidural infections, 1022–1024, suppurrative intracranial, thrombophlebitis, 1024–1025, neurologic injury, controversies, diagnosis, physiologic principles, treatment, antibiotic prophylaxis, brain tissue oxygenation, coagulopathy, contraction band necrosis, hyperglycemia, hyperthermia, hypotension, hypoxemia and respiratory management, ICP monitoring and management, neurogenic pulmonary edema, nutrition, posttraumatic seizures, posttraumatic vasospasm, prognosis, stress gastritis, thrombophylaxis, neurologic manifestations, e289–e290, Neurologic monitoring, brainstem auditory-evoked potentials (BAEP), cerebral function, cerebral perfusion, intracranial pressure monitoring/waveform interpretation, direct cerebral blood flow measurement, brain oxygen monitoring, cerebral microdialysis, cerebral vasospasm detection, intracranial pressure assessment/brain death confirmation, jugular venous oxygen saturation (SvO2), near-infrared spectroscopy (NIRS), transcranial Doppler (TCD), evoked potentials (EP), flow-metabolism coupling, anesthetics, arterial carbon dioxide and oxygen, 312–313, cerebral blood flow regulation, temperature control, pressure autoregulation, neurologic recovery optimization, cerebral perfusion, glucose control, sedation, seizure control, temperature control, Neurologic system, Neuronal cell death, neuroradiologic imaging, Neuron-specific enolase (NSE), Neurons, Neutrophils, Neutropenic enterocolitis (NE), Neutropenic patients, infections in, Neutrophil gelatinase-associated lipocalin (NGAL), Neutrophils, Nevirapine, New-onset acute kidney injury, renal function on, New-onset diabetes after transplantation (NODAT), Newton’s laws of motion, New York Heart Association (NYHA), NFA, NFA. See Near-fatal asthma, NHLBI. See National Heart, Lung, and Blood Institute, NHP. See National health program, Nicardpine, for hypertension, for ICH, Nicardpine hydrochloride, NICOM system, Nicotinamide adenine dinucleotide phosphate (NADPH), Nicotine poisoning, NIE. See Negative inspiratory force, Nifedipine, NIHSS. See National Institutes of Health Stroke Scale, Nikolsky sign, Nimodipine, for SAH, NIMS. See National Incident Management System, NINDS. See National Institute of Neurological Disorders and Stroke, NINDS study. See National Institute of Neurological Disorders and Stroke study, NIPPV. See Noninvasive positive pressure ventilation, NIRS. See Near-infrared spectroscopy, Nitrites, Nitric oxide (NO), and cardiac contractility.
Nitric oxide synthase (NOS), 159, 310
Nitroglycerin, 409, 664, 667, 1841
for hypertension, 1256t, 1258
Nitroprusside, 667, 1841, e468
Nitrous oxide, 559, e207, e216, e437
NIV. See Noninvasive ventilation
NKCC2. See Sodium-potassium-2chloride cotransporter
NMBA. See Neuromuscular blocking agent
NMBA. See Neuromuscular blocking agents
N-methyl-D-aspartate (NMDA) receptor, 90, e226
NMH. See Neuroleptic malignant syndrome
NMS. See Neuroleptic malignant syndrome
NNRTIs. See Nonnucleoside reverse transcriptase inhibitors
NOE. See Noso-oro-thromboid
Nonalcoholic fatty liver disease (NAFLD), 750
Nonalcoholic steatohepatitis (NASH), 750, e287
Nonanion gap acidosis, 1712–1713
Nonconvulsive status epilepticus (NCSE), 318, e285
Nonconvulsive seizure (NCS), 318, e285
Noncardiac surgery, 547–548
Non-beta-lactam antibiotics, e417t
Noncardiogenic pulmonary edema, e392
blood volume measurement in, 308
Nonchemical stimuli, 115
Noncorticosteroid bacterial infections, e206
Nonconvulsive seizure (NCS), 318, e285
Nonconvulsive status epilepticus (NCS), 512, 1581, 1591
Nondepolarizing muscle relaxants, e166
Nondepolarizing neuromuscular-blocking agents, 320, 320t
Nonemergency pheochromocytoma, e373
Nonhearth-beating donor, 1575
Nontunneled CVC, e110–e111
Nontuberculous mycobacterial infection, 1039
Nonocclusive mesenteric ischemia (NOMI), 1039
Nontunneled CVC, e110–e111
Nonocclusive mesenteric ischemia (NOMI), 1039
for hepatorenal syndrome, 823
for CPB surgery patient, 665
for HE, 1196t
MAP, effect on, 1656f
medullary blood flow, effect on, 1661f
renal blood flow, effect on, 1660f
urine output, effect on, 1660f
Norfloxacin, e292
Normoglycemia in intensive care
evaluation–survival using glucose algorithm regulation (NICE-SUGAR) trial, 440
Nosocomial bloodstream infection. See Bloodstream nosocomial infections
Nosocomial rhinosinusitis (NS), 958
Nosocomial sinusitis, 990
Nosocomial tracheobronchitis, 1065
NPE. See Neurogenic pulmonary edema
NPO status of patient, e184
NPPV. See Noninvasive positive pressure ventilation
NRTIs. See Nucleoside reverse transcriptase inhibitor
NSAID poisoning, e459
NSAIDs. See Nonsteroidal anti-inflammatory drugs
NSE. See Neuron–specific enolase
NSQIP. See National Surgical Quality Improvement Program
NST. See Nonstress test
NTE. See Nontrauma centers
NTIS. See Nonthyroidal illness syndrome
Nuchal rigidity, meningitis and, 1009
Nuclear magnetic resonance (NMR) spectroscopy, 426
Nuclear medicine, e268
imaging, e121
Nucleic acid amplification test (NAAT), 64, 991, 1013, e150
Nucleic acids, 540
Nucleoside reverse transcriptase inhibitor (NRTIs), 1132, 1135, 1135t, 1136t–1137t
Numerical continuous data, e21
Numerical discrete data, e21
Nuremberg Code, 24
Nurses, critical care, 34
Nursing Delirium Screening Scale (NuDESC), 1623
NUTRIC Score, e445–e446, e446t
Nutrition, 608, e128
burn injury patient and, 681
gland suppression and, e299–e300
liver transplantation and, 830–832
support, 540
Nutritional Risk Score (NRS), e445–e446, e446t
Nutritional support, in ARDS treatment, 1414
Nutritionists, 36
NYHA. See New York Heart Association
OAC. See Oral anticoagulation therapy
Obesity, 193, e196. See also Morbidly obese patient
cardiomyopathy, 748
defined, 747
tliver transplantation and, 823–824
Obesity hypoventilation syndrome (OHS), 193, e196
See also OAC.
Oral anticoagulation therapy
OCT. See Optimal external laryngeal manipulation
Ocular bobbing, 1581
Ocular Testing and brain stem reflexes, 1564
Oculocephalic reflexes test, 1581
ODM. See Organ donor management
Odontogenic infections, 1035, 1036f
Odynophagia, e322
OELM. See Optimal external laryngeal manipulation
Off-pump coronary artery bypass surgery (OPCAB), 670–671
benefits of, 671t
OFT. See Obstructive fibrinous tracheal pseudomembrane
Ogilvie syndrome, 614
Olm's law, 126, 192, 1343
OHS. See Obesity hypoventilation syndrome
Olanzapine, 1588
for delirium, 1627
Oligon, e44
Oliguria, 1443
in preeclampsia, 910
OLT. See Orthotopic liver transplantation
Omega-3 fatty acids, 540
Oncologic emergencies, 710, 1799–1814.
See also Urologic surgery and trauma
acute airway obstruction, 1805–1806
acute tumor lysis syndrome, 1801–1803
cardiac tamponade, 1808–1809
chemotherapy, toxicity of, 1811–1814
hypercalcemia, 1799–1801
neutropenic enterocolitis, 1809–1811
spinal cord compression, 1806–1808
superior vena cava syndrome, 1803–1805
Onkotic pressure, albumin and, 304, 304f
Online Antiview Index, e504
ON-Q pain relief system, 649
Onychomadesis after critical illness, 74f
OPCAB. See Off-pump coronary artery bypass surgery
Open abdomen, 618–619
Open cholecystectomy, e301
Open cricothyrotomy, e87
Open fractures, 698
Open lung approach, 1277
Open reduction/internal fixation (ORIF), 697, 730
Open surgical debridement, 619
Open system of care, 37
Open vascular surgery, 554
Operating room (OR), 172, 692
Opiate receptor complex, 559
Opiates, 318t
Opioid intoxication, e487–e489
clinical manifestations, e487t
treatment for, e488
Opioids, 560, e142, e244, e436, e487, e487t
for delirium, 1627
side effects of, 649
withdrawal, e488–e489, e488t
OPO. See Organ procurement organization
Opportunistic infections, 1114
treatment modalities for, 1118
Opsonization, 158
Optic atrophy, e467
Optic nerve, e469
Optic neuropathy, e470
Optical infrared emission sensors, 285
Optic neuritis, e471
Optimal external laryngeal manipulation (OELM), e161, e161f
OPTN. See Organ Procurement and Transplant Network
OR. See Operating room
Oral anticoagulation therapy (OAC), 757
Oral flexible bronchoscopic intubation, e145
Oral nicoamide, 95
Oral rehydration therapy (ORT), 1082, 1085
Orbital blowout fracture, 732. See also Naso-orbito-ethmoid fractures
Orchiectomy, 714
Oregon Death with Dignity Act, 17
Orellanine, e476
Organ blood flow, e199
Organ donor management (ODM), 1567
Organic acidurias, e528
Organic phosphorous compounds, e467
Organ injury minimization, 513–514
Organ Procurement and Transplant Network (OPTN), 801, 818, 1568
Organ procurement organizations (OPOs), 787, 801, 1559
Organ system dysfunction, in septic shock
cardiac manifestations, 427–428
central nervous system, 427, 427t
diabetic autonomic neuropathy, 429–430
gastrointestinal abnormalities, 428
hematologic disorders, 429
kidney, 428
liver, 428–429
metabolic disorders, 429
respiratory system, 428
ORL. See Oxygen Reserve Index
ORIF. See Open reduction/internal fixation
Oritavancin (Orbactiv), 970, 974
Oronosal masks, 1308–1309, 1308f
Oropharyngeal infection, by Candida albicans, 1035, 1035f
Orotracheal intubation, e166–e167, 729
ORT. See Oral rehydration therapy
Orthodromic AV reentry, 1231, 1231f
Orthopedic critical care
compartment syndrome, 703–704
damage control orthopedics, 699–702
709n, 700f
diagnosing musculoskeletal injury, 696
FES, 704–705
fracture fixation, 689–699
in geriatric patients, 702–703
pelvic fractures, 705–706
treatment, 696–698, 697f
Orthostatic vital signs, e264
Orthotopic liver transplantation (OLT), e281
OSA. See Obstructive sleep apnea
OSAS. See Obstructive sleep apnea syndrome
Osborne J-wave, 736
Oseltamivir, 1102e, 1103
for influenza A, 1163, 1164
Osler nodes, e413
Osmolal gap, 1711
Osmotic edema, 90
Osmotic therapy, in ICP management, 1533
Osteopenia, e394
Osteoporosis, e394
Osteoarthropathy, 1033, 1033f
Otitis externa, 1029
acute, 1029, 1030f
chronic, 1029
Otitis media
acute, 1030
chronic, 1030–1031
complications of, 1031, 1031t
with effusion, 1030
Otomycosis, 1029–1030
OUC. See Oxygen utilization coefficient
Out-of-hospital cardiac arrest, 292
Oversensing, e79
Over-the-scope clip (OTSC), e321
Overtidng, 181, 182f. See also Pressure measurements

Index

Overzealous jejunal feeding, 608
Oximeter, 204
Oxime therapy, e468
Oxycodone, e522
Oxygen
arterial carbon dioxide and, 312–313
balance, 453–455
carriage, 112
consumption, 125
discovery of, 1401
radicals, 457
regulation of CBF, 84–85, 84t
saturation, mixed venous, 125–126
saturation run, 126
therapy, e206
Oxygenation, 512–513
Oxygen challenge test, 200–201, 201t.
Oxygen consumption indexed (VO2I), 200–201, 201t.
Oxygen delivery devices, 1403–1404
Oxygen saturation, 189
level, 1404
run, 126
PACWP.
Oxynitrates, e522
Oxymetric
PAC.
See Pulmonary artery catheter
Pacemaker
Pacemaker cells, 117
Pacemaker syndrome, e79
Pacemaker threshold, e77–e78
Pace sensing, e77–e78
Pacing threshold, e77–e78
Packed red blood cells (PRBC), 1785
Packed red blood cells (PRBCs), 1745, 1747–1748
Paclitaxel, 1812
PACU.
See Postanesthetic care unit
PACWP.
See Pulmonary artery capillary wedge pressure
PAD.
See Peripheral artery disease
PAH.
See Pulmonary arterial hypertension
PAI-1.
See Plasminogen activator inhibitor-1
Pain
anesthesia, and assessment of, 224t–227t, e225–e228
assessment, e393
intensity scale, e225
Pain management
in burn injury patient, 682–683
anoxia, 683
background pain, 682
breakthrough pain, 683
patient limitations, 683
postoperative pain, 682
procedural pain, 682
in thoracotomy, 648–649
Pain management in burn injury patient, 682–683
Pain therapy, 1401
Pain, 77
Oxytetracycline, 1865t
Oxygen utilization coefficient (OUC), 230
Oxytetracycline, 1865t
Oxytocin, e542t
in uterine atony, 900
PAN.
See Pancreatic transplantation
Pancreatic transplantation
back-table work of donor pancreas, 846
anesthetic considerations, 846
back-table work of donor pancreas, 846
complications
bleeding, 848
duodenal leaks, 848–849
infections, 849
intra-abdominal infections, 849
nonsurgical, 849
Pancreatitis, 849
Papillary muscle dysfunction, 400, 1178
Papillary muscle dysfunction, 400, 1178
Papillary muscle dysfunction, 400, 1178
Papillary muscle dysfunction, 400, 1178
Papillary muscle dysfunction, 400, 1178
Papillary muscle dysfunction, 400, 1178
Pancreatitis, 539.
See also Acute pancreatitis
acute, 144, 144t
after renal transplantation, 870–871
causes, 144, 144t
diagnosis of, 144
grades of severity of, 144t
and pleural effusion, 1503–1504
posttransplant, 849
Pancreatic and bile duct surgery, 634
Pancreatic duct disruptions (PDD), e303
Pancreatic fistula, 617–618, 617t, 640, e304–e305
Pancreaticoduodenectomy (PD), 637
Pancreatic duodenal fistula, 1504
Pancreatic and bile duct surgery, 634
Pancreatic fistula, 617–618, 617t, 640, e304–e305
Pancreatic duct disruptions (PDD), e303
Pancreatic pseudocyst, e302–e303
Pancreatic surgery, complications
subsequent, 640
Pancreatic transplantation, 840–850
anesthetic considerations, 846
back-table work of donor pancreas, 846
Pancuronium, 1841, e228, e439
Pandemic infections, 1158–1171.
See also Specific infections
Pancreatic disease
Acute pancreatitis, 840
Pancreatic and bile duct surgery, 634, 634f
Pancreatic and bile duct surgery, 634, 634f
Pancreatic and bile duct surgery, 634, 634f
Pancreatic and bile duct surgery, 634, 634f
Pancreatic injury, 599
Pancreatic necrosis, e304–e306, e305t
Pancreaticoduodenectomy (PD), 637
Pancreatic pseudocyst, e302–e303
Pancreatic surgery, complications
subsequent, 640
Pancreatic transplantation, 840–850
anesthetic considerations, 846
back-table work of donor pancreas, 846
Pandemic infections, 1158–1171.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Pantocrynous, 1841, e228, e439
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Papillotomy, 727
Pantone-Valentine leukocidin (PVL), 1168
PaO2.
Paraneumonic effusions, 1504
complicated, 1504
uncomplicated, 1504
Parasympathetic nervous system, 119, e467f
Parathormone, e434
Parathyroid hormone (PTH), 1694, 1696, 1698
Paravertebral nerve blocks, 649
Parenteral nutrition (PN), 854–855, e443, e450–e451
access considerations, e450
complications, e450–e451
formula calculation, e450
Parenteral nutritional support, e311
Parenteral phosphate preparations, 1695
Parenteral nutritional support, e311
Parenteral phosphate preparations, 1695
Parental Blood Management, 1755
Pathogen-associated molecular patterns (PAMPs), 154, 373
Pathogens, e42
sources, e42
Patient capacity of, 28, 28t
cognitive abilities, informal assessments of, 28
uncooperative, combative, 28
Patient Blood Management, 1755
Patient care equipment and linen, 56
quality assessment of, 45
appropriateness measures, 44
cost-containment factor assessment, 45–46
detailing of processes, 44–45
environmental sensitivity and feedback, 45
external compliance organizations, 42
external performance improvement organizations, 42
initiatives, assessment of, 45
Institute for Health Care Improvement (IHI), 43
The Joint Commission, 42–43
Leapfrog Group, 43
outcomes, 45
quality improvement initiatives, 43–44
theoretical basis, 44
Patient monitoring, in hyperbaric chambers, e209
Patient reactions, in ICU: communication with families, sharing bad news, e7–e8, e7f, e8t
coping in, e3, e4t, e5
dependency, e6
drama/histrioniccy, e6–e7
narcissism, e5–e6
obsessinality, e6
disruptive patient-physician interactions, e1
in ICU, e1–e2, e2t
patients and families in ICU, concerns of, e2–e3
Patient transport, 56
Patient–ventilator asynchrony, during NIV, 1313
Patterns of unexpected hospital death (PURD), 222
PAV. See Proportional assisted ventilation
Proportional assist ventilation
PCA. See Posterior cerebral artery
PCC. See Prothrombin complex concentrate
PCI. See Percutaneous coronary intervention
PCIS. See Postcardiac injury syndrome
PCNL. See Percutaneous nephrostolithotripsy
POCO2. See Partial pressure of carbon dioxide
PCP. See Pneumocystis jiroveci pneumonia
PcP. See Pulmonary capillary pressure
PCT. See Procalcitonin
PCV. See Pressure control ventilation;
Pressure-control ventilation
PCV-Volume Guaranteed (PCV-VG), 1332
PCWP. See Pulmonary capillary wedge pressure
PD. See Pancreaticoduodenectomy
PDT. See Percutaneous dilatational tracheostomy
PE. See Pulmonary embolism
Peak end expiratory pressures (PEEP), 94
Peak inspiratory pressure (PIP), 1343
Pediatry, 1085
Pediatric respiratory failure, 1429–1430.
See also Extracorporeal life support (ECLS)
Pediatrics, hemorrhage shock and, 459
PEEP. See Positive end expiratory pressure
PEG. See Percutaneous endoscopic gastrostomy; Polyehtylene glycol
Pelvic fractures, 705–706
Pelvic surgery, 711–712
Pelvic retroperitoneum, 705
Pelvic infections, 711–712
Pelvis trauma, 579, e126
PEM. See Protein–energy malnutrition
Pemberton’s sign, e384
Pemphigus, e409
Penicillin, e417t
anthracy, 1148
for empyema, 1066
Penicillin-resistant pneumococci (PRP), 1054
Penrose drains, 720. See also Urologic surgery and trauma
Pentamidine isethionate, 1128
Pentobarbital coma, 1554–1555
Pepcid ulcer disease, e251, e252f, e254t
after renal transplantation, 870
Peptide nucleic acid (PNA) probes, 1045
Peptide nucleic acid fluorescent in situ hybridization (PNA-FISH), 966–967
Pepcid ulcer (PNA) probes, 1045
Pamirnavir
for influenza A, 1163
for viral infections, 1102t
Percutaneous balloon pericardiomytomy, 1246
Percutaneous cholecystotomy, e103
Percutaneous coronary intervention (PCI), 548, 756
Percutaneous cricothyroidotomy, e88
Percutaneous dilatational tracheostomy (PDT), e4193, e146, e195, e241, e241t
Percutaneous endoscopic gastrostomy (PEG), e136, e242, e306
Percutaneous feeding tubes, e134
Percutaneous fluid and abscess drainage abdominal paracentesis, e101
abscess-fistula complex, e98–e99
diagnostic/therapeutic thoracentesis, e99–e101
drainage technique, e97
empyema, e99
equipment, e97
evaluation and image guidance, e96
pancreatic collections, e99
patient preparation, e96–e97
postplacement catheter care, e98
solid organ abscess drainage, e99
suprachrionic drain placement, e101–e103
Percutaneous gastrostomy feeding tube in, e136–e137
indications, e91
pittfalls and complications, e92
technique, e91–e92
Percutaneous inferior vena cava filter placement
fluoroscopy guided, e93–e94
indications, e93
intravascular ultrasonographic-guided, e94
pittfalls and complications, e94
Percutaneous injury, 57
Percutaneous nephrostolithotripsy (PCNL), 712
Percutaneous revascularization, 401–403
Percutaneous transhepatic biliary drainage, e106
Percutaneous tube placement, e132
Perfluorocarbons (PFC), e466, e205
Perforation of hollow viscous, 147–148
Perfusion, 109
regional, regulation of, 109–110
regulation of regional, 109–110
Perfusion index (PI), 198, 205
Perfusion measurements base deficit, 460
lactate, 460
lactate versus base deficit, 460
Perianal abscesses, 992–993
Perianal infection, 992–993
diagnosis of, 992
pathogenesis of, 992
treatment of, 992–993
Periarticular humerus, 697
Pericardial disease, 1239–1248, e393
acute pericarditis, 1239–1242
cardiac tamponade, 1242–1246
coronary artery disease, e403
myocarditis, e403
pericardial constriction, 1246–1248
pericardial effusion, 1242–1246
valvular diseases, e403
Pericardial effusion, 1239–1248, e382
See also Cardiac tamponade in cancer patients, 1808–1809
diagnosis, 1243–1245, 1244f
pathophysiology, 1242–1243
treatment, 1245–1246
<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1058</td>
<td>Pneumococci, 383</td>
</tr>
<tr>
<td>1059</td>
<td>Pneumocystis \textit{pneumonia} (PCP), 1119</td>
</tr>
<tr>
<td>1059</td>
<td>arterial blood gas in, 1127</td>
</tr>
<tr>
<td>1059</td>
<td>chest radiograph, 1127, 1128f</td>
</tr>
<tr>
<td>1059</td>
<td>clinical presentation, 1127–1128</td>
</tr>
<tr>
<td>1059</td>
<td>diagnosis, 1127</td>
</tr>
<tr>
<td>1059</td>
<td>in HIV-infected patients, 1124, 1127–1129</td>
</tr>
<tr>
<td>1059</td>
<td>treatment, 1128–1129, 1128t</td>
</tr>
<tr>
<td>1059</td>
<td>ventilatory management, 1129</td>
</tr>
<tr>
<td>1059</td>
<td>\textit{Pneumocystis} \textit{proophylaxis}, e312</td>
</tr>
<tr>
<td>1064</td>
<td>community-acquired, 1053–1058</td>
</tr>
<tr>
<td>1064</td>
<td>hospital-acquired, 1053, 1056t</td>
</tr>
<tr>
<td>1064</td>
<td>postobstructive, 1520</td>
</tr>
<tr>
<td>1064</td>
<td>ventilator-associated, 1058–1064</td>
</tr>
<tr>
<td>1064</td>
<td>Pneumonia Severity Index (PSI), 1057</td>
</tr>
<tr>
<td>1064</td>
<td>Pneumoperitonium, 338–339, 339, 614</td>
</tr>
<tr>
<td>1064</td>
<td>in asthmatic patient, 1468</td>
</tr>
<tr>
<td>1064</td>
<td>causes of, 1506t</td>
</tr>
<tr>
<td>1064</td>
<td>in ICU, 1505–1506</td>
</tr>
<tr>
<td>1064</td>
<td>defined, 1505</td>
</tr>
<tr>
<td>1064</td>
<td>diagnostic evaluation, 1506–1507</td>
</tr>
<tr>
<td>1064</td>
<td>iatrogenic, 1507–1508</td>
</tr>
<tr>
<td>1064</td>
<td>primary and secondary spontaneous, 1507</td>
</tr>
<tr>
<td>1064</td>
<td>tension, 1508</td>
</tr>
<tr>
<td>1064</td>
<td>signs and symptoms of, 654</td>
</tr>
<tr>
<td>1064</td>
<td>spontaneous, 1506</td>
</tr>
<tr>
<td>1064</td>
<td>and tension pneumothoraces, 1508–1509</td>
</tr>
<tr>
<td>1064</td>
<td>traumatic, 1506</td>
</tr>
<tr>
<td>1064</td>
<td>PNPF. See Postnecrotic peripancreatic fluid collections</td>
</tr>
<tr>
<td>1064</td>
<td>PNS. See Peripheral nerve stimulation</td>
</tr>
<tr>
<td>1064</td>
<td>PO2. See Partial pressure to oxygen</td>
</tr>
<tr>
<td>1064</td>
<td>PCOD. See Postoperative cognitive dysfunction</td>
</tr>
<tr>
<td>1064</td>
<td>PCOT. See Point-of-care testing</td>
</tr>
<tr>
<td>1064</td>
<td>POD. See Postoperative delirium</td>
</tr>
<tr>
<td>1064</td>
<td>Point-of-care (POC) glucometer in critical illness, e360</td>
</tr>
<tr>
<td>1064</td>
<td>Point-of-care testing (POCT) definition, 360</td>
</tr>
<tr>
<td>1064</td>
<td>quality assurance (QA) in, 361</td>
</tr>
<tr>
<td>1064</td>
<td>accuracy, 363</td>
</tr>
<tr>
<td>1064</td>
<td>analytical sensitivity and specificity, 363</td>
</tr>
<tr>
<td>1064</td>
<td>precision, 362–363</td>
</tr>
<tr>
<td>1064</td>
<td>quality control testing, 363–364, 364t</td>
</tr>
<tr>
<td>1064</td>
<td>value of laboratory test results, 362</td>
</tr>
<tr>
<td>1064</td>
<td>recommendations for ICU, 360–361, 361t</td>
</tr>
<tr>
<td>1064</td>
<td>regulatory issues in, 364–365</td>
</tr>
<tr>
<td>1064</td>
<td>moderate-complexity tests, 366–367</td>
</tr>
<tr>
<td>1064</td>
<td>waived tests, 365–366, 366t</td>
</tr>
<tr>
<td>1925</td>
<td>Poiseuille's law, 126–127, 166</td>
</tr>
<tr>
<td>1925</td>
<td>Poisoning</td>
</tr>
<tr>
<td>1925</td>
<td>acetaminophen, e456–e458</td>
</tr>
<tr>
<td>1925</td>
<td>AChE inhibitor, e467</td>
</tr>
<tr>
<td>1925</td>
<td>acute, 316t</td>
</tr>
<tr>
<td>1925</td>
<td>alcohol, e465–e466</td>
</tr>
<tr>
<td>1925</td>
<td>antipsychotic, e459–e460</td>
</tr>
<tr>
<td>1925</td>
<td>benzodiazepine, e460</td>
</tr>
<tr>
<td>1925</td>
<td>(\beta)-adrenergic antagonist, e463–e464</td>
</tr>
<tr>
<td>1925</td>
<td>calcium channel blocker, e464–e465</td>
</tr>
<tr>
<td>1925</td>
<td>carbon monoxide, e470–e471</td>
</tr>
<tr>
<td>1925</td>
<td>cholinergic, e465–e468</td>
</tr>
<tr>
<td>1925</td>
<td>cyanide, e468</td>
</tr>
<tr>
<td>1925</td>
<td>cyclic antidepressant, e460</td>
</tr>
<tr>
<td>1925</td>
<td>digoxin, e462–e463</td>
</tr>
<tr>
<td>1925</td>
<td>lithium, e461</td>
</tr>
<tr>
<td>1925</td>
<td>salicylate, e458–e459</td>
</tr>
</tbody>
</table>
artrial blood gases, 896
body constitution, 895
cardiovascular system, 896–897, 897f
cogulation changes, 927
hemorrhagic concerns, 927–928
liver changes, 927
metabolism and respiration, 895–896
plasma proteins, colloid osmotic pressure, and GFR, 897
red blood cell, plasma, and blood volume, 897, 897f, 897t
pulmonary changes of, 897f
pulmonary edema in, 902
thrombosis and thromboembolism in, 898–899
prevention of, 944
trauma in, 934–945
Pregnancy and Lactation Labeling Rule (PLLR), e427–e428
Pregnancy-induced hypertension (PIH), 1256
Pregnant patient, coma in, 1585
Preload recruitable stroke work (PRSW), 121
Preoperative bronchodilator therapy, e144
Preoperative evaluation of high-risk surgical patient
cardiovascular
cardiac surgery, 549
noncardiac surgery, 547–548
perioperative β-blockade therapy, 549
preoperative evaluation, 549–550
neurologic system, 552
pulmonary system
intraoperative mechanical ventilation, 551–552
preoperative pulmonary optimization, 551
pulmonary evaluation, 550
pulmonary function tests, 550–551
renal system
comorbidity, 552–553
diagnostic testing, 554–555
pre-existing renal dysfunction, 553
preoperative evaluation, 554
procedure-related renal risk, 553–554
risk evaluation and stratification, 552
Preparatory phase, for critically ill patient, 67
Preparedness, 45
Prercovery liver biopsy (PLB), 1571
PRES. See Posterior reversible encephalopathy syndrome
Pressure control inverse ratio ventilation (PCIRV), 1333
Pressure-control ventilation (PCV), 1310, 1330–1333, 1346–1347, 1348f, 1419
adapting control pressure, 1331–1333, 1332f
advantage of, 1330–1331
dependent variables, 1330
independent variables, 1330
inspiratory flow waveform, 1330, 1330f
limitations of, 1331
square pressure waveform of, 1331
Pressure immobilization bandage (PIB), e498, e504
Pressure measurements, 181–188
Pressure overload, 127
Pressure-regulated volume control (PRVC), 1332, 1419
Pressure support, 1373
Pressure support mode (PSV), 1473
Pressure support ventilation (PSV), 1310, 1336–1337, 1336f, 1347–1348
Pressure ulcers, 997–999
Braden scale, 998
classification system for, 998
daniel classification, 998
eexternal causes, 997
internal causes, 997
pressure points
in sitting position, 997f
in supine position, 997f
Shea staging, 998
treatment, 998
nutritional support, 999
pressure reduction, 998
surgical intervention, 998–999
wound management, 998, 999t
Pressure-volume index (PVI), 87
Pressure-volume loop, 121, 121f, 123 during mechanical ventilation, 1345, 1345f
Pressure-volume relationships, 106–107
Pressurization rate, 1348
Preterm birth, 933
Preterm labor, 935–936
consultants on, 936
definition of, 935
evaluation of, 935–936
management, 936
risk factors for, 935
Pre-test probability, 1368
Primary care providers, 77
Primary graft dysfunction (PGD), lung transplantation and, 797–798
Primary hemostasis, 583
Primary lobule, defined, 102
Primary lymphoid organs, 155
Primary pulmonary hypertension of the newborn (PPHN), 1429
Primary survey, trauma patient
breathing, 572–573
circulation, 573–576
disability of, 576
exposure/environment, 576
Primary transport, 67
Primes polymorphonuclear leukocytes (PMN), 495
Pringle maneuver, 633
Probability distribution, defined, e18
Procarbazine, 510, 1229, 1231, 1235, 1841
Procalcitonin (PCT), 961, 978, 1562
Prochlorperazine, 218
Professional community standard, 26
Proficiency testing, 365
Professional community standard, 26
Proficiency testing, 365
Progestrone, 927, e342
Progressive multifocal leukoencephalopathy (PML), 1116, 1131
Progressive multifocal leukoencephalopathy (PMLE), 1116, 1131
Promastigote, 218
Propofol, 1229
Prophylactic antibiotics, e286
Respiratory acidosis, 1716–1717
anticipated changes in, 1831t
causes of, 1716, 1832
clinical presentation, 1716
treatment, 1716–1717
Respiratory alkalosis
anticipated changes in, 1831t
causes of, 1717, 1832
clinical presentation, 1718
and metabolic acidosis, 1719
pathophysiology, 1717–1718
treatment, 1718
Respiratory bronchiolitis, 102
Respiratory condition, in morbidly obese
patient, 748–749
Respiratory distress, 1410, e289
Respiratory failure, 1608–1609
bulbar muscles weakness, 1609
diagnostic evaluation, 1609
in HIV-infected patients, 1124, 1127
neuromuscular causes of, 1608t
noninvasive positive pressure ventilation, 1609
in transplant recipients, 882
Respiratory failure risk index, 645t
scores and outcomes, 646t
Respiratory frequency-to-tidal volume ratio, 1369–1371, 1369f, 1370f
Respiratory infections, e149–e150
Respiratory isolation, 1138
Respiratory quotient (R), 1833
Respiratory physiology, 105–106
Respiratory sinus arrhythmia, 1267
Respiratory support, in ARDS management,
Respiratory system
Respiratory tract infections, e149–e150
Respiratory tree, functional anatomy of,
and lymphocele, 873
and vascular diseases, 871
complications, early, 873
preoperative management, 862–864
posttransplant management, 862–864
blood glucose monitoring, 863
blood pressure control, 863
blood pressure monitoring, 864
bulbar muscles weakness, 1609
bulbar myopathy, 1609
bulbar weakness, 1609
bulbar weakness in transplant recipients, 1237
clinical presentation, 1236
causes of, 1235t, 1832
anticipated changes in, 1831t
and metabolic acidosis, 1719
Respiratory failure, 1608–1609
bulbar muscles weakness, 1609
diagnostic evaluation, 1609
in HIV-infected patients, 1124, 1127
neuromuscular causes of, 1608t
noninvasive positive pressure ventilation, 1609
in transplant recipients, 882
Respiratory failure risk index, 645t
scores and outcomes, 646t
Respiratory frequency-to-tidal volume ratio, 1369–1371, 1369f, 1370f
Respiratory infections, e149–e150
Respiratory isolation, 1138
Respiratory quotient (R), 1833
Respiratory physiology, 105–106
Respiratory sinus arrhythmia, 1267
Respiratory support, in ARDS management,
Respiratory system
Respiratory tract infections, e149–e150
Respiratory tree, functional anatomy of,
and lymphocele, 873
and vascular diseases, 871
complications, early, 873
preoperative management, 862–864
posttransplant management, 862–864
blood glucose monitoring, 863
blood pressure control, 863
blood pressure monitoring, 864
bulbar muscles weakness, 1609
bulbar myopathy, 1609
bulbar weakness, 1609
bulbar weakness in transplant recipients, 1237
clinical presentation, 1236
causes of, 1235t, 1832
anticipated changes in, 1831t
and metabolic acidosis, 1719
Respiratory failure, 1608–1609
bulbar muscles weakness, 1609
diagnostic evaluation, 1609
in HIV-infected patients, 1124, 1127
neuromuscular causes of, 1608t
noninvasive positive pressure ventilation, 1609
in transplant recipients, 882
Respiratory failure risk index, 645t
scores and outcomes, 646t
Respiratory frequency-to-tidal volume ratio, 1369–1371, 1369f, 1370f
Respiratory infections, e149–e150
Respiratory isolation, 1138
Respiratory quotient (R), 1833
Respiratory physiology, 105–106
Respiratory sinus arrhythmia, 1267
Respiratory support, in ARDS management,
Respiratory system
Respiratory tract infections, e149–e150
Respiratory tree, functional anatomy of,
and lymphocele, 873
and vascular diseases, 871
complications, early, 873
preoperative management, 862–864
posttransplant management, 862–864
blood glucose monitoring, 863
blood pressure control, 863
blood pressure monitoring, 864
bulbar muscles weakness, 1609
bulbar myopathy, 1609
bulbar weakness, 1609
bulbar weakness in transplant recipients, 1237
clinical presentation, 1236
causes of, 1235t, 1832
anticipated changes in, 1831t
and metabolic acidosis, 1719
Respiratory failure, 1608–1609
bulbar muscles weakness, 1609
diagnostic evaluation, 1609
in HIV-infected patients, 1124, 1127
neuromuscular causes of, 1608t
noninvasive positive pressure ventilation, 1609
in transplant recipients, 882
Respiratory failure risk index, 645t
scores and outcomes, 646t
Respiratory frequency-to-tidal volume ratio, 1369–1371, 1369f, 1370f
Respiratory infections, e149–e150
Respiratory isolation, 1138
Respiratory quotient (R), 1833
Respiratory physiology, 105–106
Respiratory sinus arrhythmia, 1267
Respiratory support, in ARDS management,
Respiratory system
Respiratory tract infections, e149–e150
Respiratory tree, functional anatomy of,
and lymphocele, 873
and vascular diseases, 871
complications, early, 873
preoperative management, 862–864
posttransplant management, 862–864
blood glucose monitoring, 863
blood pressure control, 863
blood pressure monitoring, 864
bulbar muscles weakness, 1609
bulbar myopathy, 1609
bulbar weakness, 1609
bulbar weakness in transplant recipients, 1237
clinical presentation, 1236
causes of, 1235t, 1832
anticipated changes in, 1831t
and metabolic acidosis, 1719
Respiratory failure, 1608–1609
bulbar muscles weakness, 1609
diagnostic evaluation, 1609
in HIV-infected patients, 1124, 1127
neuromuscular causes of, 1608t
noninvasive positive pressure ventilation, 1609
in transplant recipients, 882
Respiratory failure risk index, 645t
scores and outcomes, 646t
Respiratory frequency-to-tidal volume ratio, 1369–1371, 1369f, 1370f
Respiratory infections, e149–e150
Respiratory isolation, 1138
Respiratory quotient (R), 1833
Respiratory physiology, 105–106
Respiratory sinus arrhythmia, 1267
Respiratory support, in ARDS management,
Rheumatoid granuloma, e393
Rheumatoid lung nodules, e391–e392
Rhinocerebral mucormycosis, e206
Rhinoplasty surgery, 729
Rhinovirusin, 1032–1033
bacterial, 1032–1033
fungal, 1033
viral, 1033
Ribavirin, for viral infections, 1102t
Rib fractures, in thoracic trauma patient, 649
Riboflavin, 1133
Ribonucleic acid (RNA), 418
Riboflavin, 1133
Ribavirin, for viral infections, 1102t
Rivastigmine, for delirium, 1627
Rivaroxaban, 1777, e522
Risperidone, for delirium, 1627
Risk, injury, failure, loss, end-stage renal disease (RIFLE) criteria, e288
Risk assessment
delay, 1154–1155
Pathogenesis, 1154
Diagnosis, 1154
Clinical manifestations, 1154
Systolic blood pressure
Skepticism, e16
Sjögren syndrome, e398
Systemic inflammatory response
See SIRS.
Sirolimus, and nephrotoxicity, 1655t
Sirolimus, 809, 868
Sinus tachycardia, 1178, e377
Sinus rhythm, 663
Sinusitis, 990
Sinus bradycardia, 1178
Sinus arrest, 1224, 1225f
Sinoatrial (SA) conduction block, 1224,
Single nucleotide polymorphism (SNP), 537,
Single-donor platelets, 1748
Single-chamber atrial pacing, e72
Single analyte assays, e526
Sine wave, 166
Single wave, 166
Single analyte assays, e526
Single-chamber atrial pacing, e72
Single-donor platelets, 1748
Single-lung transplantation (SLT), 789
Single-lung transplantation (SLT), 789
Sinusitis, 990
Sinus arrest, 1224, 1225f
Sinus bradycardia, 1178
Sinusitis, 990
diagnosis of, 990
treatment of, 990
Sinusoid obstruction syndrome/veno-
occlusive disease (SOS/VOD) of liver,
881–882, 882t
Sinus rhythm, 663
Sinus tachycardia, 1178, e377
Sirolimus, 809, 868
adverse effects of, 868
Sirolimus, and nephrotoxicity, 1655t
SIRS. See Systemic inflammatory response
syndrome
Sjögren syndrome, e398
Skepticism, e16
Skin cancers, lung transplantation and, 800
Skin diseases. See also Dermatologic
disorders (DD)
acute generalized pustular psoriasis (von
Zumbusch type), e411
erythroderma, e411, e411t
mucous membrane pemphigoid (MMP),
e410–e412
pemphigus, e409
Skin diver’s disease, e512
Skin necrosis induced by drugs, e418
Skin pigmentation, e366
Skin wounds and musculoskeletal infection,
996–1006
fungal infections, 1000
primary bacteriologic infections, 999–1000
subcutaneous infections, 1000–1006
types of wounds
pressure/decubitus ulcers, 997–999
surgical site infections, 996–997
SLE. See Systemic lupus erythematosus
SLEDAI. See Systemic lupus erythematosus
disease activity index (SLEDAI)
Sleep apnea, e382
Sleep disorders, in geriatric patient,
771–772
background, 771–772
identification and management, 772
Slow continuous ultrafiltration (SCUF),
1674f
SMA. See Superior mesenteric artery;
Supplementary motor area
Small bowel enteroscopy, e266
Small bowel follow-through (SBFT), e270,
e271f
Small bowel transplantation (SBT), 854–859
Small bowel transplantation (SBT)
concomitant, 854–859
contraindications to, 855
future directions, 859
graft procurement, 856
graft selection, 855–856
immunosuppression regimens, 857
intestinal failure, pathophysiology of,
854–855
isolated small bowel transplant, 856, 856f
liver-inclusive graft, 859
liver-small bowel transplant, 856–857
living donor (LD), 857
multigraft transplant, 859
multivisceral transplant, 857
operative cavities, 857
outcomes
patient and graft, 858–859
social and financial, 859
patient selection, 855
posttransplant management, 857
recent trends, 859
recipient operative procedure, 856, 856f
viral infections, posttransplant, 858
wait-list, 859
Small-for-size syndrome, 835t
Small molecule kinase inhibitors, 1813
Smallpox, 1151–1152, e561
treatment and prevention, 1152
epidemiology, 1151
for hypertension, 1257–1258
and cyanide poisoning, 1258
for hypertension, 1257–1258
Sodium phenylacetate, e533
Sodium thiosulfate, e468
Sodium nitroprusside (NTP), 664, 901
and cyanide poisoning, 1258
for hypertension, 1257–1258
Sodium phenylacetate, e533
Sodium phosphatase, 265
Sodium-potassium-2chloride cotransporter
(NKCC2), 132
Sodium thiocyanate, e468
Sodium thiocyanate, e468
Solid alkali, e319
Solid organ abcess drainage, e399
Solubility of inhaled agent, 558
Somatosensory evoked potentials (SEP),
321, 322, 325, 427, 518, 1442
Somatostatin, e255, e299, e341t
Sonogram, 340
Small-vessel vasculitis, e405t
SmartCare®, 1336–1337
Smoke inhalation injury, 676
causes of, 676
Smoking, 551
Smooth endoplasmic reticulum calcium
(SERCA), 755
Snake envenomation
native, e494–e501
coral snakes, e494–e495
pit viper, e495–e501
nonnative, e501–e507
antibiotics, e505
antivenom, e503–e506
diagnosis and monitoring, e502–e503,
e504
epidemiology, e502
first aid, e504–e505
hematologic effects, e503
hospital care, e505, e505t
hypersensitivity reactions, e506–e507
local effects, e503
management, e504–e507
neurologic effects, e503–e504
nonhematologic systemic effects, e504
nonrecommended treatment, e507
Online Antivenom Index, e504
pain control, e505
pathophysiology, e502
postdischarge considerations, e507,
e507t
prehospital management, e504t
supportive therapies, e506
surgical management, e506
Snake venom, components of, e502, e502t
SNAP. See Sensory nerve action potential
SNS. See Sympathetic nervous system
Social workers, 35
Societal disasters, e572
Society for Healthcare Epidemiology of
America (SHEA), 1046
Society of Critical Care Medicine (SCCM),
35, e229, e534
The Society of Thoracic Surgeons Cardiac
Database, 670
Sodium, 1830
Sodium bicarbonate, 265
Sodium mercaptoethane sulfonate (Mesna),
881
Sodium metabolism and homeostasis, 92
Sodium nitroprusside (NTP), 664, 901
and cyanide poisoning, 1258
for hypertension, 1257–1258
Sodium phenylacetate, e533
Sodium phosphate, 265
Sodium-potassium-2chloride cotransporter
(NKCC2), 132
Sodium thiocyanate, e468
Sodium thiocyanate, e468
Solid alkali, e319
Solid organ abcess drainage, e399
Solubility of inhaled agent, 558
Somatosensory evoked potentials (SEP),
321, 322, 325, 427, 518, 1442
Somatostatin, e255, e299, e341t
Sonogram, 340

Temperature-related injuries
hyperthermia, 738–744
hypothermia, 735–738

Temporary cardiac pacemakers
alternative temporary pacing methods
external noninvasive (transcutaneous) pacing, e80
transesophageal pacing, e80
transdiaphragmatic pacing, e80
indications, e72, e73
pacemaker syndrome, e79
pace sensing and threshold determinants, e77–e78
patient assessment, e76–e77
postinsertion care, e78
temporary pacing catheters
atrial, e74–e75
dual-chamber pacing, e72
ventricular, e72–e74
transvenous pacing catheter, placement of, e77
troubleshooting, e78
venous access, e77
Temporary pacing catheters
atrial, e74–e75
dual-chamber pacing, e72
ventricular, e72–e74
Temporomandibular joint (TMJ), e393

Thermometers. See also Temperature monitoring
electronic contact, 285
infrared thermometers, 285
zero-heat-flux thermometers, 285–286
Thermoneutral zone, defined, 289

Thermoregulation
afferent input, 287
anesthetics and, 289
autonomic, 288
concentration-dependent, inhibition, 291
effector responses, 288–290
signaling in, 287
thermogenesis and energy metabolism, 290–291
transient receptor potential (TRP) channel, 287–288

Thermosensors in brain, 287
Thiamine supplementation, e482, e483
Thiazide diuretics, 132
Thiocyanate toxicity, e468
Thionamides, e379
Thiopental, e165
Thiopurine methyltransferase (TPMT), e524
Thiopurine toxicity, e524
Third-degree AV block, 1224, 1225, 1227
Thoracentesis, 1499, 1501
Thoratec PHP, 1207
Thoratec CentriMag, 1206
Thora-Klex system, 1510
Thoracic ultrasound, 1407
Thoracic trauma patient, in ICU, 649
Thoracic trauma, 578
Thoracic trauma patient, in ICU, 649
Thoracic ultrasound, 1407
Thoracoabdominal paradox, 1379
Thora-Klex system, 1510
Thoratec CentriMag, 1206
Thoratec PHP, 1207
Thrombin, 1727
Thrombin-activatable fibrinolysis inhibitor (TAFI), 533, 1726, 1728
Thrombin inhibitors, 1774–1776
Thrombin-activatable fibrinolysis inhibitor (TAFI), 533, 1726, 1728
Thrombin inhibitors, 1774–1776
Thrombin time (TT), 585, 587
Thrombocytopenia (TP), 639, 667, 1790–1793
Thrombocytopenia, 583
Thromboembolic disease, and fever, 959
Thrombogenesis and coagulation, 1761–1762, 1763f–1765f
antithrombin, 1762
couagulation cascade, regulation of, 1761–1762
fibrin, fibrinolytic degradation of, 1762
protein C pathway, 1761
tissue factor pathway inhibitor, 1761
Thrombolysis, 405, e128
Thrombolysis in myocardial infarction (TIMI) risk score, 1183
Thrombolytic therapy, 95, 402, 1777–1779, 1842
first-generation thrombolytic agents, 1777
reteplase, 1778, 1779
second-generation thrombolytics, 1778
streptokinase, 1777–1778, 1779
tenecteplase, 1779, 1779
third-generation thrombolytics, 1778
tissue-type plasminogen activator, 1778
urokinase, 1778
Thrombopoietin, e341
Thromboprophylaxis, 1535
Thrombotic microangiopathy (TMA), 1250, 1787
Thrombotic stroke, 770
Thrombotic syndromes, noncardiac, 1741
See also specific syndromes
Thrombotic thrombocytopenic purpura (TTP), 910, 1253, 1732–1733, 1787, 1794
diagnosis, 1794
pathophysiology, 1794
in pregnancy, 930
treatment, 1794
Thymoglobulin, 865
Thymus, 155
Thyroid-binding globulin (TBG), e376
Thyroid disorders
drugs and thyroid function, e376–e377, e377
hypothyroidism
cardiovascular manifestations, e382
causes of, e381
clinical manifestations of, e381, e382
clinical presentation, e382–e383
diagnosis of, e383
gastrointestinal manifestations, e382
metabolic manifestations, e382

1790–1793
metabolic manifestations, e382
hypothyroidism
cardiovascular manifestations, e382
causes of, e381
clinical manifestations of, e381, e382
clinical presentation, e382–e383
diagnosis of, e383
gastrointestinal manifestations, e382
metabolic manifestations, e382
Index

Transcutaneous carbon dioxide, measurements of, 200
Transcutaneous electrical nerve stimulation (TENS), 648
Transcutaneous oxygen, 198–199
Transcutaneous oxygen tension (PtcO2), 198
Transdiaphragmatic pressure, 1359, 1360f
Transducer, 163, 167–168
external, 168
Transduction. See also Invasive pressure monitoring
transducer design, 168
transducer properties, 167–168
Transesophageal echocardiography (TEE), 248, 287, 1210
Transesophageal pacing, e80
Transfusion-associated circulatory overload (TACO), 1751, 1754
Transfusion-related acute lung injury (TRALI), 576, 1751, 1753–1754
Transfusion requirements in critical care (TRICC) Trial, 442
Transfusion therapy, 1745–1757
alternatives, 1756
anemia and, 1746–1747
blood and blood product use, 1745
blood component modification, 1750–1751
blood loss, minimizing of, 1755
blood products
collection, 1745
storage and refrigeration, 1746
minimizing transfusion, 1755
red cell production, optimization of, 1755–1756
refusal of, 1756–1757
risks of, 1751–1753, 1751t
alloimmunization and compatibility, 1754–1755
plausible risks, 1755
transfusion reactions, 1752–1754, 1752t
transfusion-transmitted infection, 1751–1752
transfusion guidelines, 1747
cryoprecipitate, 1750, 1750t
plasma, 1749–1750, 1750t
platelets, 1748–1749, 1749f
red blood cells, 1747–1748, 1748t
whole blood, 1747
Transient ischemic attack (TIA), 771
Transient receptor potential (TRP) channel, 287–288
as putative molecular thermosensor, 287
Transillumination, e91
for hepatorenal syndrome, 823
Translaryngeal intubation, e319
Translating evidence into practice (TRiP), 46–47, 471
Translation
of HBV, 58
of influenza, 64
of VRE, 63
Transmural approach, e303
Transmural pressure, 169, 1239
Transplantation
heart, 801–813
infection after, 1113–1114, 1114f
liver, 818–835
lung, 787–801, 788f
pancreatic, 840–850
renal, 861–874
small bowel, 854–859
stem cell, 877–889
Transport phase, for critically ill patient, 67–68
Transport training, for critically ill patient, 67–68
Transport phase, for critically ill patient, 67–68
Transparenchymal pressure, 169, 1239
of VRE, 63
of HBV, 58
for hepatorenal syndrome, 823
channel, 287–288
risks of, 1751–1755, 1751t
red cell production, optimization of, 1755
minimizing transfusion, 1755
blood products
collection, 1745
blood loss, minimizing of, 1755
blood component modification, 1750–1751
blood loss, minimizing of, 1755
blood products
collection, 1745
storage and refrigeration, 1746
minimizing transfusion, 1755
red cell production, optimization of, 1755–1756
refusal of, 1756–1757
risks of, 1751–1753, 1751t
alloimmunization and compatibility, 1754–1755
plausible risks, 1755
transfusion reactions, 1752–1754, 1752t
transfusion-transmitted infection, 1751–1752
transfusion guidelines, 1747
cryoprecipitate, 1750, 1750t
plasma, 1749–1750, 1750t
platelets, 1748–1749, 1749f
red blood cells, 1747–1748, 1748t
whole blood, 1747
Trench mouth. See Acute necrotizing ulcerative gingivitis
TRH. See Thyrotropin-releasing hormone
Triage. See Critical care, e547–e548
tricotrust, e546–e547
critical care, e547–e548
mass casualty incident, e546
ventilator, 566t, 567f, e559, e564
Triaging, 18
Tricuspid annular plane systolic excursion (TAPSE), 175, 265
Tricuspid regurgitation (TR), 1218–1219
diagnosis, 1219
with enlarged annulus, 1220f
functional, 1218
pathophysiology, 1219
rheumatic, 1219
structural, 1218
treatment, 1219
Tricuspid stenosis (TS), 1218
Tridodecyl methyl ammonium chloride (TDMAC), e44
Triiodothyronine, 120, 290, e341t, e376
Trimethoprim (TMP)/sulfamethoxazole (SMX), 1078, 1870t
in PCP, 1128
Trocar technique, e98, e105
Trichomonas vaginalis (THAM) infusion, 830
Tropical ear. See Otitis externa
Tromethamine (TAM), 120
Trompynin (Tm), 120
Tropinin C, 120
Tropinin, 120, 480, 650, 1180–1181
Trousseau sign, 1697
Troponins, 120, 480, 650, 1180–1181
Troponin C, 120
Tropomyosin (Tm), 120
Trypsin, e297
True vocal cord (TVC), e391
Trypsin, e297
TSAH. See Traumatic SAH
TSH. See Thyroid-stimulating hormone
TSS. See Toxic shock syndrome
TTE. See Transthoracic echocardiography
TTJV. See Transtracheal jet ventilation
TTM. See Targeted temperature management
TTP. See Thrombotic thrombocytopenic purpura
T-tube trials, 1373–1374, 1379
Tube compensation (TC), 1338, 1338f
Tube dislodgement, e92
Tuberculin skin testing (TST), 1011, 1116
Index
Ventilator waveforms (Continued)
flow over volume (V-V loop), 1345, 1345f
functions, monitoring of, 1343–1344
patient–ventilator asynchrony and, 1353–1355
double triggering, 1353f, 1354–1355
inadequate inspiratory time, 1354
insufficient gas flow support, 1353
missed triggering, 1353–1354
reverse triggering, 1355
pressure, flow, and volume, measurement of, 1343
pressure over volume (P-V loop), 1345, 1345f
respiratory mechanics, assessment of, 1348–1355
airway resistance, 1350, 1350f
auto-PEEP, 1350, 1351f
compliance of lungs and chest wall, 1352–1353
intrathoracic/pleural pressure, 1352
pressure–time waveforms, 1351–1352
respiratory system, compliance of, 1348–1350
transpulmonary pressure, 1352, 1353f
variations in
pressure-control ventilation, 1346–1347, 1348f
pressure support ventilation, 1347–1348, 1348f, 1349f
volume-control ventilation, 1346, 1346f, 1347f
Ventilator care
chest tube management, e209
intravenous infusion devices, e209
mechanical ventilation, e208–e209
suction, e209
Ventilatory management, in CPB patients, 667
Ventriculostomy, 849
Ventral hernia repair, 619–621
Ventricular afterload, 664
pulmonary artery vasodilators, 664
pulmonary constrictors, 664
vasodilators, 664
Ventricular assist device (VAD), 396, 410, 669, 1204–1209, 1429
biventricular, 669
duration of support, 1206
dysfunction and complications of bleeding, 1208
cannula kinking, 1207
infection, 1208–1209
mechanical issues, 1208
patent foramen ovale and hypoxemia, 1208
patient factors, 1209
thrombosis and embolism, 1208
tricuspid and aortic regurgitation, 1208
ventricular dysrhythmias, 1209
flow type, 1205, 1205f, 1206f
goal of implantation, 1204
indications of, 1207
indications for, 1204
left VAD, 1207
location, 1206
mechanism, 1205
for myocardial recovery, 410
patient preparation, 1205
post-left VAD management, 1207
preoperative considerations, 1204–1205
right heart failure and, 1208
short-term, 669
ventricular dysrhythmias, 1178, e64
during pregnancy, 922
Ventricular interdependence, 1268
ventricular oversensing, e79, e79f
ventricular preload, 663–664
ventricular septal defects (VSDs), 400–401, 1178, e78
in pregnancy, 920
Ventricular tachycardia (VT), 1233–1234, 1234f
Venturi mask, 1385, 1403
Verapamil, 1843, e464
vertical transmission of HBV, 60
vestibular sense, 731
Vestibulocochlear reflexes test, 1581
Veterans Administration Hospitals (VAH), 996
Veterans Affairs Medical Centers, 645
Veterans Aging Cohort Study (VACS), 1124
VFP. See Venous foot pumps
VGE. See Vitamin K epoxide reductase (VKOR)
Ventricular septal defects (VSDs), 400–401
Ventricular afterload, 664
ventricular dysrhythmias, 1178, e64
during pregnancy, 922
Ventriculoperitoneal shunt, 855
Ventriculotomies, e207
Ventricular septal defects (VSDs), 1403
Ventricular assist device (VAD), 396, 410, 669, 1204–1209, 1429
biventricular, 669
duration of support, 1206
dysfunction and complications of bleeding, 1208
cannula kinking, 1207
infection, 1208–1209
mechanical issues, 1208
patent foramen ovale and hypoxemia, 1208
patient factors, 1209
thrombosis and embolism, 1208
tricuspid and aortic regurgitation, 1208
ventricular dysrhythmias, 1209
flow type, 1205, 1205f, 1206f
goal of implantation, 1204
indications of, 1207
indications for, 1204
left VAD, 1207
location, 1206
mechanism, 1205
for myocardial recovery, 410
small bowel transplantation, 858
varicella-zoster virus, 1103, e415–e416
viral encephalitis, 1105–1106
viral meningitis, 1104–1105
viral pathogens, in ICU, 1099f
viral pneumonitis, 1099–1100
West Nile virus (WNV), 1106–1107
Viral meningitis, 1099f, 1104–1105, 1105t
causative agents, 1010–1011
treatment for, 1016–1017
Viral pneumonitis, 1099–1100
Viral rhinosinusitis, 1033
Vinchow's triad, 688, 1483
Virtual ICU
computerized patient record, advantages, e34
computerized physician order entry, e37
computerized systems, risks of, e38–e39
errors, prevention of, e38
IT solutions for critical care
complex alerts, e36–e37
customization, e33–e36
electronic charting, e34–e35
care quality improvement, e38
remote ICU and telemedicine, e38
return on investment, e39, e39t
workload, effects on, e37
Viscosity autoregulation, 314
Visual analog scale (VAS), e224
Video bronchoscopy, e141
Video-assisted thoracic surgery (VATS), 645
lobectomy, 645
Video bronchoscopy, e141
Video laryngoscopy, e171–e172
Video-assisted thoracic surgery (VATS), 645
lobectomy, 645
Volumes of distribution, antimicrobial, 1835
Volume of distribution, antimicrobial, 1835
Volume over load, 127
Volume–pressure response (VPR), 87
Volumetric capnography, 1405
Voluntary informed consent, e53
Volutrauma, 1394, 1417, 1422
Volume clamp method, 173
Volume of distribution, antimicrobial, 1835
Volume–pressure response (VPR), 87
Volutrauma, 1394, 1417, 1422
Volume clamp method, 173
Volvom contracture, 704
Volume–pressure response (VPR), 87
Volutrauma, 1394, 1417, 1422
Volume clamp method, 173
Noninvasive cardiovascular monitoring
Volume-control ventilation (VCV), 1310, 1329–1330, 1343, 1346, 1346f, 1347f
Volume of distribution, antimicrobial, 1835
Volume over load, 127
Volume–pressure response (VPR), 87
Volumetric capnography, 1405
Voluntary informed consent, e53
Volutrauma, 1394, 1417, 1422
Volume of distribution, antimicrobial, 1835
Volume over load, 127
Volume–pressure response (VPR), 87
Volumetric capnography, 1405
Voluntary informed consent, e53
Volutrauma, 1394, 1417, 1422
Volume clamp method, 173
Noninvasive cardiovascular monitoring
Volume–pressure response (VPR), 87
Volumetric capnography, 1405
Voluntary informed consent, e53
Volutrauma, 1394, 1417, 1422

Index
Weaning

Wave speed theory, 108

Water manometer, 165

Water excretion, states of, 1684

Water bottle heart, 1244

Water balance, 1684–1685

Washout/wash-in techniques, 1407

Washing, 1754

Warm shock, 426

Warm sensors, 287

Warfarin, 1735, 1774, e264, e521–e522,

Wanglie, Helga, 12

Walled-off pancreatic necrosis (WOPN), e298

Waldenström macroglobulinemia, 161

Waived tests, 365–366

defined, 365

eamples of, 366

Wheatstone bridge, 168

West Nile virus (WNV), 1010, 1018,

West Nile neuroinvasive disease (WNND),

West Nile fever (WNF), 1106

West Nile encephalitis (WNE), 1616

Westgard quality control rules, 364, 364t

Wernicke–Korsakoff syndrome, e481

Wernicke encephalopathy, 1583

Weight gain, in pregnancy, 895

Weibel–Palade bodies, 383

Wegener granulomatosis, 1516, 1517

Weibel–Palade bodies, 383

Weight gain, in pregnancy, 895

Wernicke encephalopathy, 1583

Wernicke–Korsakoff syndrome, e481

Westgard quality control rules, 364, 364t

West Nile encephalitis (WNE), 1616

West Nile fever (WNF), 1106

West Nile neuroinvasive disease (WNND),

1106

West Nile virus (WNV), 1010, 1018,

1106–1107

clinical manifestations, 1106

diagnosis, 1106

treatment, 1106–1107

Wheatstone bridge, 168

White adipose tissue (WAT), 290, 290t

White blood cells (WBC), 373

WHO. See World Health Organization

Whole blood transfusion, 1745, 1747

Whole blood volume measurement/calculation,

306

and red cell/plasma volumes, relationship 
with, 305

Wide QRS tachycardia, 1233–1237

pre-excited tachycardia, 1234–1235,

1236f

supraventricular tachycardia with

aberrancy, 1234, 1235f

treatment of, 1235

ventricular tachycardia, 1233–1234,

1234f

Widow spider venom, e507–e508

clinical effects, e507–e508

diagnosis, e507

follow-up, e508

management, e508

pathophysiology, e507

Wiggers diagram, 121, 123f

Wilson disease, e286

Witnessed drowning, 1435t

Woods lamp, e466

Workload, effects on, e37

Work Relative Value Unit (wRVU), 628

World Federation of Neurosurgical Societies 
(WFNS) grading, 314

World Health Organization (WHO), 747,

1527

World Heart Federation (WHF), 1181

Wound abdominal, 605

in burn injury patient, management of, 
681–682

irrigation, 989

penetrating, 599

wRVU. See Work Relative Value Unit

X

Xanthine oxidase, 1561

Xenotransplantation of islets, 849

Xanomeline, 1774

X-linked ornithine transcarbamylase (OTC) deficiency, e528

XTC. See 3,4-methylenedioxymethamphetamine

Y

Yeasts, 1089. See also Fungal infections

Young–LaPlace equation, 1418

Z

Zanamivir, 1102t, 1103

for influenza A, 1163

Zargar classification of caustic injuries,

e318, e318t, e320

Zika virus, 1171

Ziralidone, for delirium, 1628

ZMC. See Zygomaticomaxillary complex

Zoledronate, for hypercalcemia of 
malignancy, 1801

Zonisamide, and nephrotoxicity, 1655t

Zoster, 180

Z-score, 1407

Zygomatic fractures, 732, 732t

Zygomaticomaxillary complex (ZMC),

731